CN117343081A - MAT2A inhibitor, pharmaceutical composition and application thereof - Google Patents
MAT2A inhibitor, pharmaceutical composition and application thereof Download PDFInfo
- Publication number
- CN117343081A CN117343081A CN202210741333.4A CN202210741333A CN117343081A CN 117343081 A CN117343081 A CN 117343081A CN 202210741333 A CN202210741333 A CN 202210741333A CN 117343081 A CN117343081 A CN 117343081A
- Authority
- CN
- China
- Prior art keywords
- membered
- cyclopropyl
- optionally substituted
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- ZTNQNZDNHUAVEI-UHFFFAOYSA-N CC=1SC2=C(N=1)C=CC(=C2)C1=C(NC=2N(C1=O)N=C(C=2C1=CC=CC=C1)C1=CC=CC=C1)NC1=NC=CC=C1 Chemical compound CC=1SC2=C(N=1)C=CC(=C2)C1=C(NC=2N(C1=O)N=C(C=2C1=CC=CC=C1)C1=CC=CC=C1)NC1=NC=CC=C1 ZTNQNZDNHUAVEI-UHFFFAOYSA-N 0.000 title abstract description 5
- 229940125535 MAT2A inhibitor Drugs 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 91
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 230000001404 mediated effect Effects 0.000 claims abstract description 5
- -1 amino, hydroxy Chemical group 0.000 claims description 140
- 238000000034 method Methods 0.000 claims description 57
- 125000003118 aryl group Chemical group 0.000 claims description 48
- 229910052739 hydrogen Inorganic materials 0.000 claims description 43
- 239000001257 hydrogen Substances 0.000 claims description 43
- 125000000623 heterocyclic group Chemical group 0.000 claims description 41
- 229910052736 halogen Inorganic materials 0.000 claims description 38
- 150000002367 halogens Chemical class 0.000 claims description 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 33
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 150000002431 hydrogen Chemical class 0.000 claims description 24
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 125000005605 benzo group Chemical group 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 108010007784 Methionine adenosyltransferase Proteins 0.000 claims description 11
- 125000004104 aryloxy group Chemical group 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 10
- 102000007357 Methionine adenosyltransferase Human genes 0.000 claims description 10
- 125000003368 amide group Chemical group 0.000 claims description 10
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 125000000468 ketone group Chemical group 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 3
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 101000947881 Homo sapiens S-adenosylmethionine synthase isoform type-2 Proteins 0.000 abstract description 12
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract description 9
- 102100035947 S-adenosylmethionine synthase isoform type-2 Human genes 0.000 abstract description 9
- 229930182817 methionine Natural products 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 75
- 238000006243 chemical reaction Methods 0.000 description 69
- 238000002360 preparation method Methods 0.000 description 64
- 238000005481 NMR spectroscopy Methods 0.000 description 59
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 59
- 239000012071 phase Substances 0.000 description 58
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 230000002829 reductive effect Effects 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 20
- 238000002953 preparative HPLC Methods 0.000 description 19
- ZFEJFNWZHUMGRH-UHFFFAOYSA-N [3-(phenylcarbamoyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(=O)NC=2C=CC=CC=2)=C1 ZFEJFNWZHUMGRH-UHFFFAOYSA-N 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 17
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 16
- 239000012299 nitrogen atmosphere Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Chemical group 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- FFWQLZFIMNTUCZ-UHFFFAOYSA-N 1-(bromomethyl)-2-fluorobenzene Chemical compound FC1=CC=CC=C1CBr FFWQLZFIMNTUCZ-UHFFFAOYSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- JPBLHOJFMBOCAF-UHFFFAOYSA-N 1,3-benzoxazol-2-amine Chemical compound C1=CC=C2OC(N)=NC2=C1 JPBLHOJFMBOCAF-UHFFFAOYSA-N 0.000 description 6
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 102100034187 S-methyl-5'-thioadenosine phosphorylase Human genes 0.000 description 6
- 101710136206 S-methyl-5'-thioadenosine phosphorylase Proteins 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- HFHFGHLXUCOHLN-UHFFFAOYSA-N 2-fluorophenol Chemical compound OC1=CC=CC=C1F HFHFGHLXUCOHLN-UHFFFAOYSA-N 0.000 description 3
- BDTRIDKONHOQQN-UHFFFAOYSA-N 4h-pyrimidin-5-one Chemical compound O=C1CN=CN=C1 BDTRIDKONHOQQN-UHFFFAOYSA-N 0.000 description 3
- LGWQAKNSIYXJPN-UHFFFAOYSA-N 5,7-dichloro-2-methylsulfanyl-[1,3]thiazolo[4,5-d]pyrimidine Chemical compound ClC1=NC(Cl)=C2SC(SC)=NC2=N1 LGWQAKNSIYXJPN-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 description 3
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 2
- GKQBXMVKFNZAOL-UHFFFAOYSA-N (3-bromophenyl)methoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=CC(Br)=C1 GKQBXMVKFNZAOL-UHFFFAOYSA-N 0.000 description 2
- ALTLCJHSJMGSLT-UHFFFAOYSA-N (3-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=CC(B(O)O)=C1 ALTLCJHSJMGSLT-UHFFFAOYSA-N 0.000 description 2
- VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
- WRMCWWKGCMDOGW-UHFFFAOYSA-N 1-bromo-3-(1-phenoxyethyl)benzene Chemical compound BrC1=CC(=CC=C1)C(C)OC1=CC=CC=C1 WRMCWWKGCMDOGW-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- IYJQYUSJVRDSGY-UHFFFAOYSA-N 2-cyclopropyl-1,3,4-oxadiazole Chemical compound C1CC1C1=NN=CO1 IYJQYUSJVRDSGY-UHFFFAOYSA-N 0.000 description 2
- LDVAIJZDACHGML-UHFFFAOYSA-N 2-fluoro-n-methylaniline Chemical compound CNC1=CC=CC=C1F LDVAIJZDACHGML-UHFFFAOYSA-N 0.000 description 2
- BQQLUQRZQOODGQ-UHFFFAOYSA-N 2-hydroxy-1-pyridin-2-ylethanone Chemical compound OCC(=O)C1=CC=CC=N1 BQQLUQRZQOODGQ-UHFFFAOYSA-N 0.000 description 2
- SBVCEYFBMGKJKV-UHFFFAOYSA-N 2-methylsulfanyl-4h-[1,3]thiazolo[4,5-d]pyrimidine-5,7-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(SC)S2 SBVCEYFBMGKJKV-UHFFFAOYSA-N 0.000 description 2
- OHXVGLQBMNCUJR-UHFFFAOYSA-N 4-pyridin-2-yl-1,3-oxazol-2-amine Chemical compound O1C(N)=NC(C=2N=CC=CC=2)=C1 OHXVGLQBMNCUJR-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- JTFITTQBRJDSTL-KVTDHHQDSA-N S-methyl-5-thio-alpha-D-ribose 1-phosphate Chemical compound CSC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H]1O JTFITTQBRJDSTL-KVTDHHQDSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- NXSSXOJYFOWWIY-UHFFFAOYSA-N [3-[[tert-butyl(dimethyl)silyl]oxymethyl]phenyl]boronic acid Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=CC(B(O)O)=C1 NXSSXOJYFOWWIY-UHFFFAOYSA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- SBTSVTLGWRLWOD-UHFFFAOYSA-L copper(ii) triflate Chemical compound [Cu+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F SBTSVTLGWRLWOD-UHFFFAOYSA-L 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- RQDSWUCVBZVOSH-UHFFFAOYSA-N ethyl 2-oxo-2-pyridin-2-ylacetate Chemical compound CCOC(=O)C(=O)C1=CC=CC=N1 RQDSWUCVBZVOSH-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 2
- 229910001623 magnesium bromide Inorganic materials 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 2
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SKLNPGGDKRKWKC-UHFFFAOYSA-N (2-chlorophenoxy)boronic acid Chemical compound OB(O)OC1=CC=CC=C1Cl SKLNPGGDKRKWKC-UHFFFAOYSA-N 0.000 description 1
- SRDKWIRBSWWARM-UHFFFAOYSA-N (2-ethynylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1C#C SRDKWIRBSWWARM-UHFFFAOYSA-N 0.000 description 1
- ONYYAVJRRZKXDI-UHFFFAOYSA-N (3-benzylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(CC=2C=CC=CC=2)=C1 ONYYAVJRRZKXDI-UHFFFAOYSA-N 0.000 description 1
- AFSSVCNPDKKSRR-UHFFFAOYSA-N (3-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Br)=C1 AFSSVCNPDKKSRR-UHFFFAOYSA-N 0.000 description 1
- FSWNRRSWFBXQCL-UHFFFAOYSA-N (3-bromophenyl)methanol Chemical compound OCC1=CC=CC(Br)=C1 FSWNRRSWFBXQCL-UHFFFAOYSA-N 0.000 description 1
- HJBGZJMKTOMQRR-UHFFFAOYSA-N (3-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=O)=C1 HJBGZJMKTOMQRR-UHFFFAOYSA-N 0.000 description 1
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 1
- QBTROWHSMGZXCV-RQURQNPSSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecoxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QBTROWHSMGZXCV-RQURQNPSSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- ACTKAGSPIFDCMF-UHFFFAOYSA-N 1,3-oxazol-2-amine Chemical compound NC1=NC=CO1 ACTKAGSPIFDCMF-UHFFFAOYSA-N 0.000 description 1
- ULMJQMDYAOJNCC-UHFFFAOYSA-N 1-(3-bromophenyl)ethanol Chemical compound CC(O)C1=CC=CC(Br)=C1 ULMJQMDYAOJNCC-UHFFFAOYSA-N 0.000 description 1
- SCBZBMXPJYMXRC-UHFFFAOYSA-N 1-(bromomethyl)-3-fluorobenzene Chemical compound FC1=CC=CC(CBr)=C1 SCBZBMXPJYMXRC-UHFFFAOYSA-N 0.000 description 1
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 1
- MOQCFMZWVKQBAP-UHFFFAOYSA-N 1-[3,5-bis(trifluoromethyl)benzoyl]-n-(4-chlorophenyl)piperidine-3-carboxamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(CCC2)C(=O)NC=2C=CC(Cl)=CC=2)=C1 MOQCFMZWVKQBAP-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- QKKGTRSHKSWYAK-UHFFFAOYSA-N 1-phenylimidazolidin-2-one Chemical compound O=C1NCCN1C1=CC=CC=C1 QKKGTRSHKSWYAK-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- RGUGZPYYMOAJLO-UHFFFAOYSA-N 2,3,6-trifluoroaniline Chemical compound NC1=C(F)C=CC(F)=C1F RGUGZPYYMOAJLO-UHFFFAOYSA-N 0.000 description 1
- YNOOQIUSYGWMSS-UHFFFAOYSA-N 2,5-difluoroaniline Chemical compound NC1=CC(F)=CC=C1F YNOOQIUSYGWMSS-UHFFFAOYSA-N 0.000 description 1
- ODUZJBKKYBQIBX-UHFFFAOYSA-N 2,6-difluoroaniline Chemical compound NC1=C(F)C=CC=C1F ODUZJBKKYBQIBX-UHFFFAOYSA-N 0.000 description 1
- OFPWMRMIFDHXFE-UHFFFAOYSA-N 2-(bromomethyl)pyridine Chemical compound BrCC1=CC=CC=N1 OFPWMRMIFDHXFE-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BYKVUGZUYJUSKD-UHFFFAOYSA-N 2-bromo-1-pyridin-2-ylethanone;hydron;bromide Chemical compound [Br-].BrCC(=O)C1=CC=CC=[NH+]1 BYKVUGZUYJUSKD-UHFFFAOYSA-N 0.000 description 1
- BBVQDWDBTWSGHQ-UHFFFAOYSA-N 2-chloro-1,3-benzoxazole Chemical compound C1=CC=C2OC(Cl)=NC2=C1 BBVQDWDBTWSGHQ-UHFFFAOYSA-N 0.000 description 1
- FTZQXOJYPFINKJ-UHFFFAOYSA-N 2-fluoroaniline Chemical compound NC1=CC=CC=C1F FTZQXOJYPFINKJ-UHFFFAOYSA-N 0.000 description 1
- NPAXPTHCUCUHPT-UHFFFAOYSA-N 3,4,7,8-tetramethyl-1,10-phenanthroline Chemical compound CC1=CN=C2C3=NC=C(C)C(C)=C3C=CC2=C1C NPAXPTHCUCUHPT-UHFFFAOYSA-N 0.000 description 1
- KHCXGFNZZRXOND-UHFFFAOYSA-N 3-(bromomethyl)pyridine Chemical compound BrCC1=CC=CN=C1 KHCXGFNZZRXOND-UHFFFAOYSA-N 0.000 description 1
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
- SJTBRFHBXDZMPS-UHFFFAOYSA-N 3-fluorophenol Chemical compound OC1=CC=CC(F)=C1 SJTBRFHBXDZMPS-UHFFFAOYSA-N 0.000 description 1
- ZNRGSYUVFVNSAW-UHFFFAOYSA-N 3-nitrophenylboronic acid Chemical compound OB(O)C1=CC=CC([N+]([O-])=O)=C1 ZNRGSYUVFVNSAW-UHFFFAOYSA-N 0.000 description 1
- KRLKXOLFFQWKPZ-UHFFFAOYSA-N 4-(bromomethyl)pyridine Chemical compound BrCC1=CC=NC=C1 KRLKXOLFFQWKPZ-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- VCZJVXLWQTXSPQ-UHFFFAOYSA-N 4-methyl-1,3-oxazol-2-amine Chemical group CC1=COC(N)=N1 VCZJVXLWQTXSPQ-UHFFFAOYSA-N 0.000 description 1
- DYYFCNDEROYKKJ-UHFFFAOYSA-N 5-methyl-1,3-oxazol-2-amine Chemical group CC1=CN=C(N)O1 DYYFCNDEROYKKJ-UHFFFAOYSA-N 0.000 description 1
- VFEXODVWKUOZBF-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-methyl-2-phenyl-3-piperidin-1-yl-1H-pyrazolo[1,5-a]pyrimidin-7-one Chemical compound Cc1nc2c(N3CCCCC3)c([nH]n2c(=O)c1-c1ccc(O)cc1)-c1ccccc1 VFEXODVWKUOZBF-UHFFFAOYSA-N 0.000 description 1
- JSIBZFQOVIDMRH-UHFFFAOYSA-N 6-bromo-2,4-dichlorothieno[3,2-d]pyrimidine Chemical compound ClC1=NC(Cl)=C2SC(Br)=CC2=N1 JSIBZFQOVIDMRH-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- SODRECDKCZSAEI-UHFFFAOYSA-M Br[Mg]CC1CC1 Chemical compound Br[Mg]CC1CC1 SODRECDKCZSAEI-UHFFFAOYSA-M 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- WVTXALOGXQZDHJ-UHFFFAOYSA-N C(C)(C)(C)P(C1=C(C=CC=C1)C1=C(C=C(C=C1C(C)C)C(C)C)C(C)C)C(C)(C)C.CS(=O)(=O)O Chemical group C(C)(C)(C)P(C1=C(C=CC=C1)C1=C(C=C(C=C1C(C)C)C(C)C)C(C)C)C(C)(C)C.CS(=O)(=O)O WVTXALOGXQZDHJ-UHFFFAOYSA-N 0.000 description 1
- 101100434927 Caenorhabditis elegans prmt-5 gene Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229940125761 Compound 6g Drugs 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 230000000970 DNA cross-linking effect Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 241000662429 Fenerbahce Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 229940123776 Immuno-oncology therapy Drugs 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 201000005027 Lynch syndrome Diseases 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000005927 Myosarcoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 208000037276 Primitive Peripheral Neuroectodermal Tumors Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 102100026115 S-adenosylmethionine synthase isoform type-1 Human genes 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- PHTMVIAGTMTVSK-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1=CC=CN2N=C(N)N=C21 PHTMVIAGTMTVSK-UHFFFAOYSA-N 0.000 description 1
- ACYLEYDBPWXTIO-UHFFFAOYSA-N [3-(cyclopropylcarbamoyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(=O)NC2CC2)=C1 ACYLEYDBPWXTIO-UHFFFAOYSA-N 0.000 description 1
- BIXQPMDLILBJKW-UHFFFAOYSA-M [Br-].[Mg+]CC1CCC1 Chemical compound [Br-].[Mg+]CC1CCC1 BIXQPMDLILBJKW-UHFFFAOYSA-M 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 150000003997 cyclic ketones Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- JFYKIEHOOZWARC-UHFFFAOYSA-N cyclopropanecarbohydrazide Chemical compound NNC(=O)C1CC1 JFYKIEHOOZWARC-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- CRHWEIDCXNDTMO-UHFFFAOYSA-N ditert-butylphosphane Chemical compound CC(C)(C)PC(C)(C)C CRHWEIDCXNDTMO-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical group [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000016847 malignant urinary system neoplasm Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- FKJCGJZRRAPSHH-UHFFFAOYSA-N methyl 4-(carbamoylamino)-2-methylsulfanyl-1,3-thiazole-5-carboxylate Chemical compound COC(=O)C=1SC(SC)=NC=1NC(N)=O FKJCGJZRRAPSHH-UHFFFAOYSA-N 0.000 description 1
- GVNAJKLESILZHU-UHFFFAOYSA-N methyl 4-amino-2-methylsulfanyl-1,3-thiazole-5-carboxylate Chemical compound COC(=O)C=1SC(SC)=NC=1N GVNAJKLESILZHU-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical group Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 201000004435 urinary system cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an MAT2A inhibitor, a pharmaceutical composition and application thereof, wherein the structure of the MAT2A inhibitor is shown as a general formula (I), and the definition of each substituent is shown in the specification. The compound shown in the formula (I) has remarkable MAT2A inhibition activity and can be used for preventing and/or treating Methionine Adenosine Transferase (MAT) mediated diseases or disease states.
Description
Technical Field
The invention belongs to the field of biological medicine, and particularly relates to an MAT2A inhibitor, a pharmaceutical composition and application thereof.
Background
Cancer is a leading cause of death worldwide. A limitation of mainstream therapeutic methods, such as chemotherapy and immunotherapy, is that their cytotoxic effects are not limited to cancer cells, but adverse reactions can occur in normal tissues. Thus, new strategies are needed to better target cancer cells.
Methionine Adenosyltransferase (MAT), also known as S-adenosylmethionine synthetase, is a cellular enzyme that catalyzes the synthesis of S-adenosylmethionine (SAM or AdoMet) from methionine and ATP, and is considered to be the rate-limiting step in the methionine cycle. In the liver, methionine circulation has an additional function, mainly to rapidly remove excessive methionine in the blood after high methionine or high protein diet, and finally to be transported to other organs through homocysteine, cysteine, cystathionine, glutathione.
Methionine adenosyltransferase 2A (MAT 2A) is an enzyme that utilizes methionine and ATP to produce SAM. SAM is the primary methyl donor in cells for methylation of a variety of substrates including DNA, RNA and proteins. One methylase using SAM as a methyl donor is the protein arginine N-methyltransferase 5 (PRMT 5). Although SAM is required for PRMT5 activity, PRMT5 is competitively inhibited by 5' Methylthioadenosine (MTA). Since MTA is part of the methionine salvage pathway, the MTA level of the cell remains low during the initiation of the methionyl phosphorylase (MTAP).
MAT2A is a target of anti-tumor therapy because it plays a vital role in promoting liver cancer cell growth. Recent studies have shown that silencing by using small interfering RNAs substantially inhibits the growth of hepatoma cells and induces apoptosis. Some MTAP-deficient cancer cell lines are particularly sensitive to inhibiting MAT2A, an enzyme that is widely expressed in normal tissues that catalyzes the conversion of methylthioadenosine to adenine and 5-methylthioribose-1-phosphate. Adenine is remedied to produce adenosine monophosphate, and 5-methylthioribose-1-phosphate is converted to methionine and formate. Because of this salvage pathway, MTA can be an alternative source of purine when de novo synthesis of purine is blocked by, for example, antimetabolites such as L-alacinone. In other cancers lacking MTAP deletions (including hepatocellular carcinoma and leukemia), MAT2A is deregulated. Silencing MAT2A expression by RNA interference can produce antiproliferative effects in a variety of cancer models, many human and murine malignant cells lack MTAP activity. MTAP deficiency is present not only in tissue culture cells, but also in primary leukemias, gliomas, melanomas, pancreatic cancers, non-small cell lung cancer (NSCLC), bladder cancers, astrocytomas, osteosarcomas, head and neck cancers, myxochondrosarcoma, ovarian cancers, endometrial cancers, breast cancers, soft tissue sarcomas, non-hodgkin lymphomas and mesothelioma.
Thus, finding novel and effective MAT2A inhibitors may provide a novel treatment for cancer patients (including those with MTAP-deficient tumors), an important direction in current tumor-targeted drug development.
Disclosure of Invention
The object of the present invention is to provide a novel MAT2A inhibiting compound, which compounds and their pharmaceutical compositions are useful in methods of treating a variety of cancers, including those refractory to standard therapies such as surgery, radiation therapy, chemotherapy and hormonal therapy.
In an embodiment of the present invention, the present invention provides a compound represented by the general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the general formula (I) has the structure:
wherein:
R 1 or R is 2 Each independently selected from hydrogen, halogen, C1-C6 alkyl or C2-C6 alkynyl;
X 1 selected from N or CR a ;
X 2 Selected from N or CH;
R a selected from hydrogen, halogen, C1-C6 alkyl, amino, hydroxy, amido, 3-6 membered cycloalkyl, 5-7 membered heterocyclyl, benzo five membered heterocyclyl, 5-7 membered heteroaryl orWherein the C1-C6 alkyl is optionally substituted with hydroxy, 5-10 membered aryl, 5-10 membered aryloxy, halogen substituted 5-10 membered aryloxy, or 3-6 membered cycloalkyl, the amido is optionally substituted with C1-C6 alkyl, C1-C6 haloalkyl, 3-6 cycloalkyl, 5-10 membered aryl, halogen substituted 5-10 membered aryl, or halogen substituted 5-10 membered aralkyl, the amino is optionally substituted with 9-12 membered fused ring heteroaryl, 5-10 membered heteroaryl, C1-C3 alkyl substituted 5-10 membered heteroaryl, or pyridinyl substituted 5-10 membered heteroaryl, the hydroxy is optionally substituted with 5-10 membered aralkyl, 5-10 membered heteroaralkyl, halogen substituted 5-10 membered aralkyl, or a benzo five membered heterocyclyl, the 5-7 membered heterocyclyl is optionally substituted with 5-10 membered aryl, the 5-7 membered heteroaryl is optionally substituted with 3-6 membered cycloalkyl;
Alternatively, R a And R is R 1 And form a 3-6 membered heterocyclic ketone group with the carbon atom to which they are attached, said 3-6 membered heterocyclic ketone group being optionally substituted with a 5-7 membered aryl group or a 5-7 membered aralkyl group;
R 3 selected from hydrogen, C1-C6 alkyl, 5-10 membered aryl, C2-C6 alkenyl, 3-6 membered cycloalkyl, C1-C6 alkylthio or C1-C6 sulfonyl, said C1-C6 alkyl being optionally substituted by 3-6 membered cycloalkyl;
R 4 and R is 5 Each independently selected from hydrogen or C1-C6 alkyl.
In a further preferred embodiment of the invention, R 1 Selected from hydrogen, halogen or C2-C3 alkynyl; preferably hydrogen, chlorine or acetylene; more preferably hydrogen or chlorine; most preferred is hydrogen.
In a further preferred embodiment of the invention, R 2 Selected from hydrogen or halogen; preferably hydrogen or chlorine; more preferably hydrogen.
In a further preferred embodiment of the invention, X 1 Is CR (CR) a 。
In a further preferred embodiment of the invention, X 2 Is N.
In a further preferred embodiment of the invention, R a Selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, amino, hydroxy, amido, 3-4 membered cycloalkyl, 5 membered heterocyclyl, benzo five membered heterocyclyl containing 1-3 heteroatoms selected from N or O,5 membered heteroaryl orThe C1-C3 alkyl group is optionally substituted with a hydroxy, 5-7 membered aryl, 5-7 membered aryloxy, halogen substituted 5-7 membered aryloxy, or 3-4 membered cycloalkyl, the amido group is optionally substituted with a C1-C3 alkyl, C1-C3 haloalkyl, 3-4 membered cycloalkyl, 5-7 membered aryl, halogen substituted 5-7 membered aryl, or halogen substituted 5-7 membered aralkyl, the amino group is optionally substituted with a 9 membered fused ring heteroaryl containing 1-3 heteroatoms selected from N or O, a 5-7 membered heteroaryl, a C1-C3 alkyl substituted 5-7 membered heteroaryl, or a pyridinyl substituted 5-7 membered heteroaryl, the hydroxy group is optionally substituted with a 5-7 membered aralkyl, a 5-7 membered heteroaralkyl, a halogen substituted 5-7 membered aralkyl, or a benzo five membered heterocyclyl containing 1-3 heteroatoms selected from N or O, the 5 membered heterocyclyl group is optionally substituted with a 5-7 membered aryl, the 5-membered heteroaryl is optionally substituted with a 3 membered cycloalkyl;
Preferably, R a Selected from the group consisting of hydrogen, bromine, C1-C3 alkyl, amino, hydroxyl, amido, cyclopropyl, The C1-C3 alkyl is optionally substituted with hydroxy, cyclopropyl, phenyl, Substituted, said amide optionally being methyl, trifluoroethyl, cyclopropyl, phenyl,/-> Substituted, said amino group is optionally +.> Substituted, the hydroxy group optionally being Substitution, said->Optionally substituted by phenyl, said ++> Optionally substituted with cyclopropyl;
more preferably, R a Selected from hydrogen, bromine,
Further preferably, R a Selected from hydrogen, bromine,
Still more preferably, R a Selected from bromine,
In a further preferred embodiment of the invention, R a And R is R 1 And form a 5 membered heterocyclic ketone group with the carbon atom to which they are attached, optionally substituted with a 5-7 membered aryl or 5-7 membered aralkyl group;
preferably, R a And R is R 1 Form with the carbon atom to which they are attachedOptionally substituted with phenyl or benzyl;
more preferably, R a And R is R 1 Formation of carbon atoms to which they are attached
In a further preferred embodiment of the invention, R 3 Selected from hydrogen, C1-C3 alkyl, phenyl, C2-C4 alkenyl, 3-4 membered cycloalkyl, C1-C3 alkylthio or C1-C3 sulfonyl, said C1-C3 alkyl being optionally substituted by cyclopropyl;
preferably, R 3 Selected from hydrogen, methyl, ethyl, cyclopropyl, phenyl,
More preferably, R 3 Is cyclopropyl.
In a further preferred embodiment of the invention, R 4 And R is 5 Each independently selected from hydrogen or C1-C3 alkyl; preferably hydrogen or methyl; more preferably, R 4 And R is 5 And is methyl.
In a further preferred embodiment of the present invention, the compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof is further represented by formula (II-1):
wherein,
R 1 、R 3 、R 4 、R 5 as described in general formula (I) above.
In a further preferred embodiment of the present invention, the compound represented by the general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, which is further represented by the general formula (II-2),
wherein R is 3 、R 4 、R 5 、R a As described in general formula (I) above.
In a further preferred embodiment of the present invention, the compound represented by the general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, which is further represented by the general formula (II-3),
wherein R is 3 、R 4 、R 5 As described in the general formula (I) above,
R 6 selected from hydrogen, phenyl or benzyl.
In a further preferred embodiment of the present invention, the compound represented by the general formula (II-2), a stereoisomer thereof or a pharmaceutically acceptable salt thereof is further represented by the general formula (III):
wherein:
L is selected from the group consisting of bond, -O-, -NH-, - (CH) 2 ) m -、 Wherein (1)>Is the site linked to the "benzene ring">Is the site of attachment to "ring C";
R C and R is D Each independently selected from hydrogen or C1-C3 alkyl;
ring C is selected from 3-6 membered cycloalkyl, 3-6 membered heterocyclyl, 5-7 membered aryl, 5-7 membered heteroaryl, 5-7 membered heterocyclyl, 9-12 membered fused ring heteroaryl, or benzo five membered heterocyclyl, said 3-6 membered cycloalkyl, 3-6 membered heterocyclyl, 5-7 membered aryl, 5-7 membered heteroaryl, or benzo five membered heterocyclyl optionally being further substituted with halogen, C1-C3 alkyl, 3-6 membered cycloalkyl, 5-7 membered aryl, or 5-7 membered heteroaryl;
R 3 、R 4 、R 5 as described in general formula (I) above;
m is 1 or 2;
z is 0, 1 or 2.
In a further preferred embodiment of the invention, L is selected from the group consisting of bond, -O-, -NH-, - (CH) 2 ) m -、 Wherein R is C And R is D Each independently selected from hydrogen or methyl, m is 1, z is 0 or 1;
preferably, L is selected from the group consisting of bond, -O-, -NH-, -CH 2 -、
More preferably, L is selected from the group consisting of a bond, -NH-
In a further preferred embodiment of the invention, ring C is selected from 3-6 membered cycloalkyl, 5-7 membered aryl, 5-7 membered heterocyclyl, 9 membered fused ring heteroaryl, 5-7 membered heteroaryl or benzo five membered heterocyclyl containing 1-3 heteroatoms selected from N or O, said 5-7 membered heteroaryl optionally being substituted with C1-C3 alkyl, 3-6 membered cycloalkyl or 5-7 membered heteroaryl, said 5-7 membered aryl optionally being substituted with halogen, said 5-7 membered heterocyclyl optionally being substituted with 5-7 membered aryl;
Preferably, ring C is selected from cyclopropyl, Wherein said->Optionally substituted by methyl or pyridyl, said +.>Optionally substituted with benzene, said ++>Optionally substituted by cyclopropyl, said +.>Optionally substituted with fluorine;
more preferably, ring C is selected from cyclopropyl,
Further preferably, ring C is selected from cyclopropyl,
In a further preferred embodiment of the present invention, the compound, stereoisomer or pharmaceutically acceptable salt thereof has the structure:
in a further preferred embodiment of the invention, the compoundsHas the following isomers:
in a further preferred embodiment of the invention, the compoundsHas the following isomers:
in a preferred form of the invention, the invention also provides a pharmaceutical composition comprising a therapeutically effective amount of any of the compounds described above, stereoisomers thereof, or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers.
The pharmaceutical compositions of the invention may be administered by any suitable route or method, for example by oral or parenteral (e.g. intravenous) administration. For administration by the oral route, the pharmaceutical compositions of the present invention are typically provided in the form of tablets, capsules or solutions. A tablet may comprise a compound of the invention, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Such carriers include, but are not limited to, diluents, disintegrants, binders, lubricants, colorants, or preservatives. The capsule comprises hard capsule and soft capsule. Examples of suitable oral dosage forms are tablets comprising about 1mg, 2mg, 5mg, 10gm, 15mg, 25mg, 50mg, 100mg, 250mg, 500mg, 750mg, 1000mg, 1250mg, 1500mg, 1750mg or 2000mg of a compound of the invention.
For parenteral administration, the pharmaceutical compositions of the present invention may be administered by intravenous injection, intramuscular injection or subcutaneous injection. It is usually provided as a sterile aqueous solution or suspension or lyophilized powder and is adjusted for proper pH and isotonicity.
In a preferred form of the invention, the invention also provides the use of a compound of any one of the above, a stereoisomer or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prophylaxis and/or treatment of a Methionine Adenosyltransferase (MAT) -mediated disease or condition.
In a preferred form of the invention, the invention also provides a method for the prevention and/or treatment of Methionine Adenosyltransferase (MAT) -mediated diseases or conditions comprising administering to a subject in need thereof a compound of the invention, a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention.
In a preferred mode of the invention, examples of such Methionine Adenosyltransferase (MAT) -mediated diseases or conditions include, but are not limited to, cancer, such as pancreatic cancer, bladder cancer, neuroblastoma, intestinal cancer such as rectal cancer, colon cancer, familial adenomatous polyposis cancer and hereditary non-polyposis colorectal cancer, esophageal cancer, lip cancer, laryngeal cancer, hypopharynx cancer, tongue cancer, salivary gland carcinoma, gastric cancer, adenocarcinoma, medullary thyroid cancer, papillary thyroid cancer, renal parenchymal cancer, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, choriocarcinoma, prostate cancer, testicular cancer, breast cancer, urinary system cancer, melanoma, brain tumors such as glioblastoma, astrocytoma, meningioma, neuroblastoma and peripheral neuroectodermal tumors hodgkin's lymphoma, non-hodgkin's lymphoma, burkitt's lymphoma, acute Lymphoblastic Leukemia (ALL), chronic Lymphocytic Leukemia (CLL), acute Myelogenous Leukemia (AML), chronic Myelogenous Leukemia (CML), adult T-cell leukemia, hepatocellular carcinoma, gall bladder carcinoma, bronchogenic carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, multiple myeloma, basal cell tumor, teratoma, retinoblastoma, choriocarcinoma, seminoma, rhabdomyosarcoma, craniopharyngeoma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, ewing's sarcoma, and plasmacytoma.
The compounds of the invention, stereoisomers or pharmaceutically acceptable salts thereof, or pharmaceutical compositions of the invention may be administered prior to, simultaneously with, or after radiation therapy or cytostatic or anti-tumour chemotherapy. Suitable cytostatic chemotherapeutic compounds include, but are not limited to, (i) antimetabolites, such as cytarabine; (ii) a DNA-cleaving agent, such as bleomycin; (iii) DNA cross-linking agents, such as cisplatin; (iv) intercalating agents, such as doxorubicin; (v) protein synthesis inhibitors, such as L-asparaginase; (vi) topoisomerase I poisons, such as topotecan; (vii) topoisomerase II poisons, such as etoposide; (viii) microtubule targeting agents such as vinblastine; (ix) kinase inhibitors such as f staurosporine; (x) various test agents, such as thioplatin; polyphenols such as quercetin; (xi) hormones, such as glucocorticoids; (xii) hormone antagonists such as tamoxifen.
The compounds of the invention, stereoisomers or pharmaceutically acceptable salts thereof, or the pharmaceutical compositions of the invention, may be used alone or in combination with an immunooncology therapy.
The compounds of the invention, stereoisomers thereof, or pharmaceutically acceptable salts thereof, or the pharmaceutical compositions of the invention may also be used in combination with radiation therapy.
Correlation definition
Unless specifically indicated, the following terms used in the specification and claims have the following meanings:
the "compounds" of the invention may be asymmetric, e.g., have one or more chiral centers. Unless otherwise indicated, "compounds" of the present invention refer to any one stereoisomer or a mixture of two or more stereoisomers. Stereoisomers include, but are not limited to, enantiomers and diastereomers. The asymmetric carbon atom-containing compounds of the present invention may be isolated in optically pure form or as a mixture of two or more stereoisomers. Optically pure forms can be resolved from mixtures of two or more stereoisomers, or synthesized by using chiral starting materials or chiral reagents. The "compounds" of the present invention also include tautomeric forms. Tautomers originate from the exchange of one single bond with an adjacent double bond and accompany the migration of one proton.
The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
The term "halogen" refers to fluorine, chlorine, bromine and iodine.
The term "member" refers to the number of backbone atoms or groups of atoms that make up the ring. For example, "5-10 membered" means that the number of backbone atoms or groups of atoms that make up the ring is 5, 6, 7, 8, 9, or 10. Thus, for example, pyridine, piperidine, piperazine and benzene are six-membered rings, while thiophene and pyrrole are five-membered rings.
The term "substituted" means that any one or more hydrogen atoms on a particular group is substituted with a substituent, provided that the valence of the particular group is normal and the substituted compound is stable. For example, "substituted with halogen" means that any one or more hydrogen atoms on a particular group is substituted with halogen, so long as the valence of the particular group is normal and the substituted compound is stable.
Numerical ranges herein refer to individual integers within a given range. For example, "C1-C6" means that the group may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms; "C1-C3" means that the group may have 1 carbon atom, 2 carbon atoms, or 3 carbon atoms.
The term "alkyl" refers to a saturated aliphatic hydrocarbon group, including straight or branched chain saturated hydrocarbon groups, having the indicated number of carbon atoms. The term "C1-C6 alkyl" includes C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, C6 alkyl, examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, 2-pentyl, 3-pentyl, n-hexyl, 2-hexyl, 3-hexyl, and the like.
The term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced with halogen atoms (fluorine, chlorine, bromine, iodine), as the term "C1-C6 haloalkyl" refers to a haloalkyl group containing 1 to 6 carbon atoms, examples of which include, but are not limited to, trifluoromethyl, trifluoroethyl.
The term "amino" refers to-NH 2 。
The term "hydroxy" refers to-OH.
The term "amide" refers to-CO-NH 2 。
The term "cycloalkyl" refers to a monocyclic saturated hydrocarbon system, free of heteroatoms, and free of double bonds. Examples of the term "3-6 membered cycloalkyl" include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
The term "heterocyclyl" refers to saturated cyclic ketones wherein the carbonyl carbon atom is included in the heterocycloalkyl group, wherein one or more of the ring atoms is a heteroatom selected from nitrogen, oxygen or S, the remaining ring atoms being carbon, preferably a 5-7 membered heterocyclyl group, more preferably a 5-membered heterocyclyl group. Examples of the term "5-7 membered heterocyclic ketone group" include
The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent. The term "3-6 membered heterocyclyl" comprising 3 to 6 ring atoms, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S, the remaining ring atoms being carbon, preferably wherein 1 to 3 are heteroatoms.
The term "benzo five-membered heterocyclic group" refers to a ring system formed by the condensation of a benzene ring and a five-membered heterocyclic ringThe benzene ring and the five-membered heterocyclic group share a pair of adjacent ring atoms, and the connection site with the parent nucleus structure is positioned at the benzene ring part. Wherein the heterocyclic moiety is a saturated, partially unsaturated or fully unsaturated ring system having ring carbon atoms and 1 to 3 ring heteroatoms or groups of heteroatoms independently selected from nitrogen, sulfur, oxygen, sulfoxide, sulfone,Examples include, but are not limited to, ">
The term "aryl" refers to an all-carbon monocyclic or fused bicyclic aromatic ring radical having a conjugated pi-electron system, which is obtained by removing one hydrogen atom from a single carbon atom of the parent aromatic ring system. Including bicyclic groups fused to saturated, partially unsaturated, or aromatic carbocyclic rings; examples include, but are not limited to, phenyl, naphthyl, anthracenyl, indene, indane, 1, 2-dihydronaphthalene, 1,2,3, 4-tetrahydronaphthalene. The term "5-10 membered aryl" refers to a 5-10 membered aromatic ring group. The term "halogen substituted 5-10 membered aryl" refers to a 5-10 membered aromatic ring group, the hydrogen atoms on the aromatic group of which are further substituted with halogen, examples include, but are not limited to,
The term "heteroaryl" refers to a monovalent aryl group comprising at least one heteroatom independently selected from nitrogen, oxygen, and sulfur. Examples of "5-to 10-membered heteroaryl" include, but are not limited to, pyridinyl, thienyl, imidazolyl, pyrimidinyl, pyridinyl, furanyl, pyrazinyl, thiazolyl.
The term "fused ring heteroaryl" refers to an aromatic heterocyclic group formed by two or more cyclic structures sharing two adjacent atoms with each other, comprising at least one heteroatom independently selected from nitrogen, oxygen and sulfur. Examples include but are not limited to,
the term "aralkyl" refers to an alkyl group substituted with an aryl group. Aralkyl groups described herein are preferably C1-C6 alkyl groups substituted with aryl groups, more preferably C1-C3 alkyl groups substituted with aryl groups. Examples include, but are not limited to,the term "5-10 membered aralkyl" refers to an alkyl group substituted with a 5-10 membered aryl group. The term "halogen substituted 5-10 membered aralkyl" refers to a 5-10 membered aralkyl further substituted with halogen, examples include, but are not limited to,/-and->
The term "heteroarylalkyl" refers to an alkyl group substituted with a heteroaryl group. Examples include, but are not limited to,
the term "aryloxy" refers to a group formed by attachment of oxygen to an aromatic group. The term "5-10 membered aryloxy" refers to a group formed by attachment of oxygen to a 5-10 membered aromatic group, examples of which include, but are not limited to, The term "halogen substituted 5-10 membered aryloxy" refers to a group formed by attachment of oxygen to a 5-10 membered aromatic group, the hydrogen atoms of which are further substituted with halogen, examples include, but are not limited to, ">
And/or +.>Is->Refers to a chemical bond junction. When present in bicyclic or polycyclic ringsAnd/or +.>And in the case of an indeterminate connection position, it means that the connection site is limited to +.>And/orAny atom on the monocyclic ring where it is located is permissible only in terms of valency.
The term "pharmaceutically acceptable" means that the carrier, vehicle, adjuvant, diluent, and/or salt formed is generally chemically or irrational compatible with the other ingredients comprising the pharmaceutical dosage form, and physiologically compatible with the recipient.
The term "pharmaceutically acceptable carrier" refers to those carriers which have no significant irritating effects on the body and which do not impair the biological activity and properties of the active compound. Including but not limited to any diluents, disintegrants, binders, glidants, wetting agents permitted by the national food and drug administration to be useful in humans or animals.
The term "pharmaceutically acceptable salt" refers to salts that retain the biological effectiveness of the free acids and bases of the particular compounds without biological adverse effects. Such as acid (including organic and inorganic acids) addition salts or base addition salts (including organic and inorganic bases), and may also include zwitterionic salts, and also include quaternary ammonium salts, such as alkylammonium salts. Pharmaceutically acceptable salts of the invention can be synthesized from the parent compound containing an acid or base by conventional chemical methods. In general, the preparation of such salts is as follows: prepared via reaction of these compounds in free acid or base form with a stoichiometric amount of the appropriate base or acid in water or an organic solvent or a mixture of both. Salts of the present invention include, but are not limited to, hydrochloride, sulfate, citrate, oxalate, malate, and fumarate.
The term "effective amount" or "therapeutically effective amount" refers to a sufficient amount of a drug or agent that is non-toxic but achieves the desired effect. The precise dosage will vary depending on a variety of factors, such as subject-dependent variables (e.g., age, immune system health, etc.), disease or disorder, and the treatment being administered.
The abbreviations used in the claims and the specification have the following meanings:
M:mol/L
mM:mmol/L
μM:μmol/L
nM:nmol/L;
DMSO: dimethyl sulfoxide
1H NMR: nuclear magnetic resonance hydrogen spectrum
LCMS: liquid phase mass spectrum combination
The term "pharmaceutical composition" means a composition comprising a compound described in the present disclosure or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable ingredient selected from the following, including but not limited to: carriers, diluents, adjuvants, excipients, preservatives, fillers, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, antibacterial agents, antifungal agents, lubricants, dispersing agents, temperature sensitive materials, temperature adjusting agents, adhesives, stabilizers, suspending agents, and the like.
The medicaments or pharmaceutical compositions of the present disclosure can be administered orally, topically, parenterally, or mucosally (e.g., buccally, by inhalation, or rectally) in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers. It is generally desirable to use the oral route. The active agent may be administered orally in the form of capsules, tablets, etc. (see Remington: the Science and Practice of Pharmacy,20th Edition).
The medicaments or pharmaceutical compositions of the present disclosure may be administered parenterally, i.e. by intravenous (i.v.), intraventricular (i.c.v.), subcutaneous (s.c.), intraperitoneal (i.p.), intramuscular (i.m.), subcutaneous (s.d.), or intradermal (i.d.), by direct injection, via bolus injection or continuous infusion, for example. Formulations for injection may be presented in unit dosage form, for example, in ampules or multi-dose containers with added preservative. The compositions may take the form of suspensions, solutions or emulsions in oily or aqueous vehicles, in the form of excipients (vehicles), and may contain formulatory agents such as anti-settling agents, stabilisers and/or dispersants. Alternatively, the active ingredient may be reconstituted in powder form with a suitable carrier (e.g. sterile pyrogen-free water) prior to use.
The medicaments or pharmaceutical compositions of the present disclosure may also be formulated for rectal administration, for example, as suppositories or retention enemas (e.g., containing conventional suppository bases such as cocoa butter or other glycerides).
The term "treating" includes inhibiting, alleviating, preventing or eliminating one or more symptoms or side effects associated with the disease, condition or disorder being treated.
The terms "reduce", "inhibit", "reduce" or "reduce" are used relative to a control. One skilled in the art will readily determine the appropriate controls for each experiment. For example, a reduced response in a subject or cell treated with a compound is compared to a response in a subject or cell not treated with the compound.
Detailed Description
The preparation methods of the compounds of the present invention are described more specifically below, but these specific preparation methods do not set any limit to the scope of the present invention. In addition, the reaction conditions such as reactants, solvents, bases, amounts of compounds used, reaction temperatures, reaction times, and the like are not limited to the following examples.
The compounds of the present invention may also be conveniently prepared by optionally combining the various synthetic methods described in this specification or known in the art, such combination being readily carried out by one of ordinary skill in the art.
Examples section
Example 1:4- (2-chlorophenyl) -2-cyclopropyl-7- (methylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of 4- (carbamoylamino) -2- (methylsulfanyl) -1, 3-thiazole-5-carboxylic acid methyl ester
Methyl 4-amino-2- (methylsulfanyl) -1, 3-thiazole-5-carboxylate (5.00 g) and dissolved in methylene chloride (75 mL), chlorosulfonyl isocyanate (4.85 g) was added dropwise under nitrogen at-78 ℃, the reaction system was stirred at 0 ℃ for 30 minutes, the residue obtained by concentration under reduced pressure was dissolved in 4N hydrochloric acid (12 mL), stirred at 100 ℃ for 40 minutes, the reaction system was cooled to room temperature, and the precipitated solid was collected by filtration and washed with water (3×30 mL) and dried in vacuo to give the title compound 5.9g.
b) Preparation of 2- (methylsulfanyl) -4H,6H- [1,3] thiazolo [4,5-d ] pyrimidine-5, 7-dione
4- (carbamoyl) -2- (methylthio) -1, 3-thiazole-5-carboxylic acid methyl ester (5.90 g), methanol (200 mL), an methanolic ammonia solution (100 mL, 7M in MeOH) were added to a 500mL sealed tube, the reaction system was heated to stirring at 80℃for 5 hours, the reaction system was cooled to room temperature, and the resulting title compound was concentrated under reduced pressure to 4.8g.
c) Preparation of 5, 7-dichloro-2- (methylthio) - [1,3] thiazolo [4,5-d ] pyrimidine
2- (methylthio) -4H,6H- [1,3] thiazolo [4,5-d ] pyrimidine-5, 7-dione (3.50 g) was dissolved in phosphorus oxychloride (70 mL), stirred overnight at 110℃under nitrogen atmosphere, the reaction was cooled to room temperature, the resulting residue was concentrated under reduced pressure, the reaction was quenched by the addition of saturated aqueous sodium bicarbonate (100 mL) at 0℃and extracted with ethyl acetate (3X 50 mL), the combined organic layers were washed with saturated brine (1X 50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the title compound 3.2g.
d) Preparation of 5-chloro-N-methyl-2- (methylsulfanyl) - [1,3] thiazolo [4,5-d ] pyrimidin-7-amine
5, 7-dichloro-2- (methylthio) - [1,3] thiazolo [4,5-d ] pyrimidine (3.50 g), methylamine hydrochloride (1.41 g) were added dropwise to N-methylpyrrolidone (70 mL), N-diisopropylethylamine (7.18 g), the reaction was stirred under nitrogen at room temperature for 3 hours, extracted with ethyl acetate (3X 50 mL), the combined organic layers were washed with saturated brine (1X 100 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the evaporated residue was washed with dichloromethane/ethyl acetate/petroleum ether (1/1/1) (3X 10 mL) to give the title compound 1.38g.
e) Preparation of 7- (methylamino) -2- (methylsulfanyl) -4H- [1,3] thiazolo [4,5-d ] pyrimidin-5-one
5-chloro-N-methyl-2- (methylsulfanyl) - [1,3] thiazolo [4,5-d ] pyrimidin-7-amine (700 mg) was added to acetic acid (14 mL), the reaction system was stirred under nitrogen at 100℃for 48 hours, concentrated under reduced pressure, and the solid was collected by filtration and washed with diethyl ether/dichloromethane=1:1 (3X 5 mL) to give 620mg of the title compound.
f) Preparation of 2-methanesulfonyl-7- (methylamino) -4H- [1,3] thiazolo [4,5-d ] pyrimidin-5-one
7- (methylamino) -2- (methylsulfanyl) -4H- [1,3] thiazolo [4,5-d ] pyrimidin-5-one (100 mg) was dissolved in water (1 mL) and acetonitrile (1 mL), hydrogen peroxide (441.99 mg) was added in portions, the reaction system was stirred under nitrogen at room temperature for 4 hours, the reaction solution was concentrated under reduced pressure to 5mL, the reaction system was adjusted to pH7 with saturated aqueous sodium carbonate solution, and the precipitated solid was collected by filtration and washed with brine (3X 5 mL) to give 50mg of the title compound.
g) Preparation of 2-cyclopropyl-7- (methylamino) -4H- [1,3] thiazolo [4,5-d ] pyrimidin-5-one
2-methanesulfonyl-7- (methylamino) -4H- [1,3]Thiazolo [4,5-d]Pyrimidin-5-one (10 mg) was dissolved in tetrahydrofuran (0.50 mL) and cooled to-10℃and magnesium bromide (cyclopropyl) was added in portions under nitrogen (0.058 mL). The reaction was stirred at-10 ℃ for 1 hour and warmed to room temperature and stirred at room temperature for a further 2 hours. The reaction was quenched by addition of saturated aqueous ammonium chloride (0.5 mL), filtered, the filter cake washed with N, N-dimethylformamide (3 x2 mL), and the filtrate concentrated under reduced pressure and purified by preparative HPLC to give 10mg of the title compound under the following conditions (column: xselect CSH OBD Column x 150mm 5 μm; mobile phase a: water (10 MMOL/LNH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 5%B to 40%B in 8min,40%B; the wavelength is 220nm; RT1 (mi)n):5.87)。
h) Preparation of 4- (2-chlorophenyl) -2-cyclopropyl-7- (methylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
2-cyclopropyl-7- (methylamino) -4H- [1,3]Thiazolo [4,5-d]Pyrimidine-5-one (10 mg), 2-chlorophenyl boric acid (10.55 mg), 4-di-tert-butylbipyridine (12.08 mg), copper acetate (24.52 mg), N-dimethylformamide (0.50 mL) were added to a reaction flask, pyridine (35.59 mg) was added dropwise thereto, the reaction mixture was stirred at 60℃overnight, filtered, the cake was washed with dichloromethane/methanol (1/1) (3X 5 mL), the filtrate was concentrated under reduced pressure, and purified by Prep-HPLC to give the title compound 2.7mg under the following conditions (chromatographic column: xselect CSH OBD Column X150 mm 5 μm; mobile phase A: water (10 MMOL/LNH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient of 5% B to 60% B in 8min, wavelength of 220nm; RT1 (min): 6.32).
1 H NMR(400MHz,DMSO-d 6 )δ8.31(d,J=4.8Hz,1H),7.67–7.57(m,1H),7.46(dtt,J=9.9,7.1,3.9Hz, 3H),2.92(d,J=4.5Hz,3H),2.44(dq,J=8.5,4.8,4.3Hz,1H),1.27–1.14(m,2H),0.87(dt,J=8.5,6.1Hz, 2H).
LCMS m/z=333[M+1] +
Example 2 4- (2-chlorophenyl) -7- (methylamino) -2- (methylsulfanyl) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of 4- (2-chlorophenyl) -7- (methylamino) -2- (methylsulfanyl) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
7- (methylamino) -2- (methylsulfanyl) -4H- [1,3] thiazolo [4,5-d ] pyrimidin-5-one (1 g), 2-chlorophenylboronic acid (1.03 g), 4-di-tert-butylbipyridine (1.18 g), copper triflate (475.30 mg) were added to N, N-dimethylformamide (20.00 mL), pyridazine (3.51 g) was added dropwise at room temperature, the reaction mixture was stirred overnight at 60℃and concentrated under reduced pressure, and the residue was evaporated to dryness and purified by column chromatography (mobile phase: dichloromethane/methanol=25/1 (V/V)) to give 600mg of the title compound.
1 H NMR(400MHz,DMSO-d 6 )δ8.36(d,J=4.7Hz,1H),7.65-7.62(m,1H),7.48(dh,J=5.6,2.8Hz,3H), 2.93(d,J=3Hz,3H),2.67(s,3H).
LCMS m/z=339[M+1] +
Example 3 4- (2-chlorophenyl) -2-methanesulfonyl-7- (methylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of 4- (2-chlorophenyl) -2-methanesulfonyl-7- (methylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
4- (2-chlorophenyl) -7- (methylamino) -2- (methylthio) - [1,3]Thiazolo [4,5-d]Pyrimidine-5-one (100.00 mg) was added to water (1 mL) and acetonitrile (1 mL), hydrogen peroxide (297.79 mg) was added in portions under nitrogen atmosphere, stirred at room temperature until the reaction was complete, the reaction mixture was filtered, the filter cake was washed with ethanol (3X 5 mL), the filtrate was concentrated under reduced pressure and purified by preparative HPLC to give the title compound 7.1mg under the following conditions (column: xselect CSH OBD Column X150 mm 5 μm; mobile phase A: water (10 MMOL/L NH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 5%B to 55%B in 8min; the wavelength is 220nm; RT1 (min): 5.9).
1 H NMR(400MHz,DMSO-d 6 )δ8.97(d,J=4.7Hz,1H),7.72–7.64(m,1H),7.58–7.47(m,3H),3.42(s, 3H),3.00(d,J=4.5Hz,3H).
LCMS m/z=371[M+1] +
Example 4 4- (2-chlorophenyl) -2-ethyl-7- (methylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of 4- (2-chlorophenyl) -2-ethyl-7- (methylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
4- (2-chlorophenyl) -2-methanesulfonyl-7- (methylamino) - [1,3]Thiazolo [4,5-d]Pyrimidin-5-one (30.00 mg) additionInto tetrahydrofuran (0.6 mL), a tetrahydrofuran solution (0.162 mL) of ethylmagnesium bromide was added in portions under nitrogen at-10℃and the reaction was stirred at-10℃for 1 hour and at room temperature for 2 hours, quenched with saturated aqueous ammonium chloride (1 mL), filtered, the filter cake was washed with N, N-dimethylformamide (3X 2 mL), the filtrate was concentrated under reduced pressure and purified by preparative HPLC to give the title compound 2mg under the following conditions (Column: XBridge Prep OBD C Column, 30X 150mm,5 μm; mobile phase A: water (10 mmol/L NH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 5%B to 42%B in 8min; the wavelength is 220nm; RT1 (min): 7.37).
1 H NMR(400MHz,DMSO-d 6 )δ8.38(d,J=4.8Hz,1H),7.68–7.59(m,1H),7.53–7.42(m,3H),3.01– 2.91(m,5H),1.22(t,J=7.4Hz,3H).
LCMS m/z=321[M+1] +
Example 5 4- (2-chlorophenyl) -2-methyl-7- (methylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 4 by substituting methyl magnesium bromide for ethyl magnesium bromide in step a).
1 H NMR(400MHz,DMSO-d 6 )δ8.37(d,J=4.8Hz,1H),7.63(dd,J=5.9,3.1Hz,1H),7.47(tq,J=5.5, 3.0Hz,3H),2.93(d,J=4.5Hz,3H),2.65(s,3H).
LCMS m/z=307[M+1] +
Example 6 4- (2-chlorophenyl) -7- (methylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of 4- (2-chlorophenyl) -7- (methylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
4- (2-chlorophenyl) -2-methylsulfonyl-7- (methylamino) - [1,3]]Thiazolo [4,5-d]Pyrimidin-5-one (10.00 mg) was added to tetrahydrofuran (0.25. 0.25 mL) and ethanol (0.25 mL), sodium borohydride (2.04 mg) was added in portions under nitrogen, the reaction system was stirred overnight at room temperature under nitrogen, and the title compound 1.8mg was purified by preparative HPLC under the following conditions (column: YMC-actual Triart C18, 30X 150mm,5 μm mobile phase A: water (10 mmol/LNH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 5%B to 35%B in 8min, wavelength 220nm; RT1 (min): 7.03).
1 H NMR(400MHz,DMSO-d 6 )δ9.23(s,1H),8.55(d,J=4.8Hz,1H),7.68–7.60(m,1H),7.54–7.46(m, 3H),2.95(d,J=4.4Hz,3H).
LCMS m/z=293[M+1] +
Example 7 4- (2-chlorophenyl) -7- (methylamino) -2-phenyl- [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 4 by substituting phenylmagnesium bromide for ethylmagnesium bromide in step a).
1 H NMR(400MHz,DMSO-d 6 )δ8.59(d,J=5.0Hz,1H),7.82–7.76(m,2H),7.72–7.65(m,1H),7.61– 7.47(m,6H),2.98(d,J=4.3Hz,3H).
LCMS m/z=369[M+1] +
Example 8 2- (but-3-en-1-yl) -4- (2-chlorophenyl) -7- (methylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 4 by substituting ethyl magnesium bromide in step a) with bromo (cyclopropylmethyl) magnesium.
1 H NMR(400MHz,DMSO-d 6 )δ8.40(d,J=5.2Hz,1H),7.68–7.59(m,1H),7.48(dh,J=5.5,2.9Hz, 3H),5.79(ddt,J=16.8,10.3,6.5Hz,1H),5.04-4.99(m,2H),3.05(t,J=7.4Hz,2H),2.93(d,J=4.5Hz,3H), 2.37(q,J=7.1Hz,2H).
LCMS m/z=347[M+1] +
Example 9 4- (2-chlorophenyl) -2- (cyclobutylmethyl) -7- (methylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 4 by substituting ethyl magnesium bromide in step a) with bromo (cyclobutylmethyl) magnesium.
1 H NMR(400MHz,DMSO-d 6 )δ8.37(d,J=4.7Hz,1H),7.63(dd,J=5.8,3.3Hz,1H),7.47(tq,J=5.4, 2.9Hz,3H),3.04(d,J=7.5Hz,2H),2.93(d,J=4.5Hz,3H),2.61–2.51(m,1H),2.00(dq,J=10.9,6.6,4.9Hz, 2H),1.88–1.66(m,4H).
LCMS m/z=361[M+1] +
EXAMPLE 10 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -N-phenylbenzamide
a) Preparation of 5-chloro-N, N-dimethyl-2- (methylthio) - [1,3] thiazolo [4,5-d ] pyrimidin-7-amine
5, 7-dichloro-2- (methylthio) - [1,3] thiazolo [4,5-d ] pyrimidine (6.1 g), dimethylamine hydrochloride (2.96 g) were added dropwise to N-methylpyrrolidone (122 mL), N-diisopropylethylamine (12.51 g), the reaction was stirred at room temperature under a nitrogen atmosphere for 3 hours, extracted with ethyl acetate (3X 50 mL), the combined organic layers were washed with saturated brine (1X 100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the title compound 6g.
b) Preparation of 7- (dimethylamino) -2- (methylthio) -4H- [1,3] thiazolo [4,5-d ] pyrimidin-5-one
5-chloro-N, N-dimethyl-2- (methylthio) - [1,3] thiazolo [4,5-d ] pyrimidin-7-amine (6 g) was added to acetic acid (200 mL), and the reaction system was stirred under nitrogen at 100℃for 48 hours and concentrated under reduced pressure to give the title compound 4g.
c) Preparation of 7- (dimethylamino) -2-methanesulfonyl-4H- [1,3] thiazolo [4,5-d ] pyrimidin-5-one
7- (dimethylamino) -2- (methylthio) -4H- [1,3] thiazolo [4,5-d ] pyrimidin-5-one (2 g) was dissolved in water (20 mL) and acetonitrile (20 mL), hydrogen peroxide (8.33 g) was added in portions, the reaction system was stirred under nitrogen at room temperature for 2 hours, the reaction solution was concentrated under reduced pressure, and the residue was evaporated to dryness and purified by column chromatography (mobile phase: dichloromethane/methanol=20/3 (V/V)) to give the title compound 1g.
d) Preparation of 2-cyclopropyl-7- (dimethylamino) -4H- [1,3] thiazolo [4,5-d ] pyrimidin-5-one
7- (dimethylamino) -2-methanesulfonyl-4H- [1,3] thiazolo [4,5-d ] pyrimidin-5-one (200 mg) was dissolved in tetrahydrofuran (2.67 mL) and cooled to-10℃and magnesium bromide (cyclopropyl) was added in portions under nitrogen (0.16 mL). The reaction was stirred at-10 ℃ for 1 hour and warmed to room temperature, stirred at room temperature for 2 hours, quenched by addition of saturated aqueous ammonium chloride (1 mL), filtered, concentrated under reduced pressure, and the residue evaporated to dryness was purified by column chromatography (mobile phase: dichloromethane/methanol=5/1 (V/V)) to give 80mg of the title compound.
e) Preparation of 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -N-phenylbenzamide
2-cyclopropyl-7- (dimethylamino) -4H- [1,3]Thiazolo [4,5-d]Pyrimidine-5-one (50 mg), 3- (phenylcarbamoyl) phenylboronic acid (76.51 mg), 4-di-tert-butylbipyridine (56.80 mg), copper triflate (229.59 mg), N-dimethylformamide (1 mL) were added to a reaction flask, pyridine (167.38 mg) was added dropwise thereto, the reaction mixture was stirred overnight at 40℃under an oxygen atmosphere, filtered, and the filtrate was concentrated under reduced pressure and purified by Prep-HPLC to give the title compound 60mg under the following conditions (column: YMC-structures Triart C18, 30X 150mm, 5 μm; mobile phase A: water (10 mmol/LNH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 15%B to 60%B in 8min, 60% B;the wavelength is UV220 nm; RT1 (min) 8.08; column temperature 25 deg.c).
1 H NMR(400MHz,DMSO-d 6 )δ10.30(s,1H),8.01(dt,J=7.9,1.4Hz,1H),7.89(t,J=1.9Hz,1H),7.81 –7.73(m,2H),7.64(t,J=7.8Hz,1H),7.52(ddd,J=7.9,2.1,1.1Hz,1H),7.36(dd,J=8.6,7.3Hz,2H),7.17 –7.02(m,1H),3.32(s,6H),2.46–2.37(m,1H),1.24–1.13(m,2H),0.96–0.82(m,2H).
LCMS m/z=432[M+1] +
Example 11 2-cyclopropyl-7- (dimethylamino) -4- [3- (1-phenoxyethyl) phenyl ] - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of 1-bromo-3- (1-phenoxyethyl) benzene
1- (3-bromophenyl) ethanol (500 mg), phenol (234.04 mg), triphenylphosphine (1.1 g) and tetrahydrofuran (5 mL) were added to a reaction flask, diisopropyl azodicarboxylate (854.84 mg) was added dropwise at 0℃under a nitrogen atmosphere, the reaction system was stirred at room temperature for 2 hours, the reaction solution was decompressed, and the residue was evaporated to dryness and purified by column chromatography (mobile phase: petroleum ether/ethyl acetate=10/1 (V/V)), to give 170mg of the title compound.
b) Preparation of 3- (1-phenoxyethyl) phenylboronic acid
1-bromo-3- (1-phenoxyethyl) benzene (6 g) was dissolved in tetrahydrofuran (90 mL), n-butyllithium (1.66, g) was added dropwise at-78 ℃ under nitrogen atmosphere, the reaction system was stirred at-78 ℃ for 30 minutes, trimethyl borate (3.37 g) was added, gradually warmed to room temperature, stirred for 1 hour, 2M aqueous hydrochloric acid (20 mL) and ice water (300 mL) were added to quench the reaction, extraction was performed with ethyl acetate (3×200 mL), the combined organic layers were washed with saturated brine (2×300 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was evaporated to dryness and purified by column chromatography (mobile phase: petroleum ether/ethyl acetate=10/1 (V/V)), to give 1.2g of the title compound.
c) Preparation of 2-cyclopropyl-7- (dimethylamino) -4- [3- (1-phenoxyethyl) phenyl ] - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 10 by replacing 3- (phenylcarbamoyl) phenylboronic acid in step e) with 3- (1-phenoxyethyl) phenylboronic acid.
1 H NMR(400MHz,DMSO-d 6 )δ7.46–7.40(m,2H),7.32(d,J=1.9Hz,1H),7.25–7.19(m,2H),7.19– 7.16(m,1H),6.94–6.84(m,3H),5.52(q,J=6.4Hz,1H).3.29–3.29(m,6H),2.39(td,J=8.3,4.2Hz,1H), 1.55(d,J=6.4Hz,3H),1.22–1.11(m,2H),0.94–0.77(m,2H).
LCMS m/z=433[M+1] +
Example 12 2-cyclopropyl-7- (dimethylamino) -4- [3- (phenoxymethyl) phenyl ] - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 11 by substituting 3- (1-phenoxyethyl) phenylboronic acid in step c) with 3- (phenoxymethyl) phenylboronic acid.
1 H NMR(400MHz,DMSO-d 6 )δ7.52(dd,J=4.8,1.3Hz,2H),7.40(d,J=2.2Hz,1H),7.34–7.24(m, 3H),7.06–7.00(m,2H),6.95(t,J=7.3Hz,1H),5.15(s,2H),3.35(s,6H),2.45(dd,J=8.3,4.6Hz,1H),1.26 –1.17(m,2H),0.96–0.87(m,2H).
LCMS m/z=419[M+1] +
Example 13 4- [3- (1, 3-Benzooxazol-2-ylamino) phenyl ] -2-cyclopropyl-7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of 4- (3-bromophenyl) -2-cyclopropyl-7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 10 by replacing 3- (phenylcarbamoyl) phenylboronic acid in step e) with 3-bromophenylboronic acid.
b) 4- [3- (1, 3-Benzooxazol-2-ylamino) phenyl group]-2-cyclopropyl-7- (dimethylamino) - [1,3]Thiazolo [4,5-d]Preparation of pyrimidin-5-one 4- (3-bromophenyl) -2-cyclopropyl-7- (dimethylamino) - [1,3]Thiazolo [4,5-d]Pyrimidine-5-one (80 mg), 2-aminobenzoxazole (82.27 mg), potassium carbonate (39.56 mg), methanesulfonic acid (2-di-tert-butylphosphino-2 ',4',6 '-triisopropyl-1, 1' -biphenyl) (2 '-amino-1, 1' -biphenyl-2-yl) palladium (II) (32.48 mg), t-butanol (1 mL) were added to a reaction flask, heated to 100deg.C under nitrogen atmosphere and stirred for 3 hours, and the title compound 7.5mg was purified by preparative HPLC under the following conditions (column: YMC-acts Triart C18, 30 x 150mm,5 μm; mobile phase A: water (10 mmol/LNH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 20% B to 45% B in 8min,45% B; the wavelength is 220nm; RT1 (min): 7.02).
1 H NMR(400MHz,DMSO-d 6 )δδ10.80(s,1H),7.73(dt,J=6.3,1.8Hz,2H),7.53–7.39(m,3H),7.22(td, J=7.6,1.2Hz,1H),7.14(td,J=7.7,1.3Hz,1H),6.93(dt,J=7.9,1.4Hz,1H),3.34(d,J=6.6Hz,6H),2.42 (td,J=8.3,4.1Hz,1H),1.18(dt,J=8.1,3.5Hz,2H),0.95–0.88(m,2H).
LCMS m/z=445[M+1] +
EXAMPLE 14 (E) -N "-cyano-N' - {3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] phenyl } -N-phenylguanidine
a) Preparation of 2-cyclopropyl-7- (dimethylamino) -4- (3-nitrophenyl) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 10 by replacing 3- (phenylcarbamoyl) phenylboronic acid in step e) with 3-nitrophenylboronic acid.
b) Preparation of 4- (3-aminophenyl) -2-cyclopropyl-7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
2-cyclopropyl-7- (dimethylamino) -4- (3-nitrophenyl) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one (70 mg), methanol (3 mL), palladium on carbon (2 mg) were added to a reaction flask, stirred at room temperature under a hydrogen atmosphere for 2 hours, filtered, and the filter cake was washed with methanol (2X 2 mL) and concentrated under reduced pressure to give 80mg of the title compound.
c) Preparation of (Z) -N' -cyano-N- {3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] phenyl } -1-phenoxyformamidine
4- (3-Aminophenyl) -2-cyclopropyl-7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one (80 mg), cyano (diphenoxymethylene) amine (116.43 mg) were dissolved in isopropanol (2 mL), stirred at room temperature under nitrogen for 2 hours, concentrated under reduced pressure, and the residue was purified by column chromatography (mobile phase: dichloromethane/methanol=20/3 (V/V)) to give the title compound 15mg.
d) Preparation of (E) -N "-cyano-N' - {3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] phenyl } -N-phenylguanidine
(Z) -N' -cyano-N- {3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3]Thiazolo [4,5-d]Mixture base of pyrimidine-4-, and its use]Phenyl } -1-phenoxyformamidine (15 mg), aniline (14.81 mg), 1, 4-dioxane (1 mL) were added to a reaction flask, and the reaction was stirred at 110℃for 2 hours, purified by Prep-HPLC to give 0.3mg of the title compound under the following conditions (column: YMC-actual Triart C18 ExRS, 30X 150mm, 5 μm; mobile phase A: water (10 mmol/LNH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 15%B to 50%B in 8min, 50% B; the wavelength is UV220 nm; RT1 (min) 7.28; column temperature 25 deg.c).
LCMS m/z=471[M+1] +
Example 15 2-cyclopropyl-7- (dimethylamino) -4- (3- { [1,2,4] triazolo [1,5-a ] pyridin-2-ylamino } phenyl) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
/>
Prepared according to the method of example 13 by substituting 2-aminobenzoxazole in step b) with [1,2,4] triazolo [1,5-a ] pyridin-2-amine.
1 H NMR(400MHz,DMSO-d 6 )δ9.77(s,1H),8.78(d,J=6.7Hz,1H),7.69(d,J=7.9Hz,1H),7.62(t,J =2.0Hz,1H),7.59–7.50(m,2H),7.37(t,J=8.1Hz,1H),7.09–6.93(m,1H),6.75(d,J=7.7Hz,1H),3.32(s, 6H),2.43(d,J=8.2Hz,1H),1.22–1.12(m,2H),0.91(dd,J=4.6,2.8Hz,2H).
LCMS m/z=445[M+1] +
Example 16 2-cyclopropyl-7- (dimethylamino) -4- [3- (1, 3-oxazol-2-ylamino) phenyl ] - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method described in example 13, substituting 2-aminobenzoxazole in step b) with oxazol-2-amine.
1 H NMR(400MHz,DMSO-d 6 )δ10.24(s,1H),7.65(d,J=1.0Hz,1H),7.60–7.50(m,2H),7.37(t,J= 7.9Hz,1H),6.96(d,J=1.0Hz,1H),6.87–6.68(m,1H),3.31(s,6H),2.47–2.36(m,1H),1.18(dd,J=8.1, 3.0Hz,2H),0.90(dd,J=4.7,2.7Hz,2H).
LCMS m/z=395[M+1] +
EXAMPLE 17 4- [3- (benzyloxy) phenyl ] -2-cyclopropyl-7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of 4- [3- (benzyloxy) phenyl ] -2-cyclopropyl-7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
4- (3-bromophenyl) -2-cyclopropyl-7- (dimethylamino) - [1,3]Thiazolo [4,5-d]Pyrimidine-5-one (20 mg), benzyl alcohol (8.29 mg), copper iodide (0.97 mg), 3,4,7, 8-tetramethyl-1, 10-phenanthroline (2.42 mg), cesium carbonate (24.98 mg), toluene (1.5 mL) were added to a microwave tube, reacted with microwaves at 150℃for 4 hours, and purified by Prep-HPLC to give the title compound2.1mg of the compound, purified by a chromatographic Column of XBridge Prep OBD C Column,30 x 150mm,5 μm; mobile phase A Water (10 mmol/LNH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1 mL/min; gradient 30%B to 70%B in 8min,70%B; the wavelength is UV 220nm; RT1 (min) 6.33; column temperature 25 deg.c).
1 H NMR(400MHz,DMSO-d 6 )δ7.48–7.44(m,2H),7.42–7.34(m,4H),7.07–7.03(m,1H),6.94(t,J= 2.4Hz,1H),6.86–6.81(m,1H),5.10(s,2H),3.28(s,6H),2.42(t,J=4.8Hz,1H),1.21–1.16(m,2H),0.91– 0.87(m,2H).
LCMS m/z=419[M+1] +
Example 18 2-cyclopropyl-7- (dimethylamino) -4- {3- [ (5-methyl-1, 3-oxazol-2-yl) amino ] phenyl } - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method described in example 13, substituting 5-methyl-1, 3-oxazol-2-amine for 2-aminobenzoxazole in step b).
1 H NMR(400MHz,DMSO-d 6 )δ10.07(s,1H),7.52(dq,J=7.8,1.2Hz,2H),7.35(td,J=7.6,1.4Hz, 1H),6.86–6.71(m,1H),6.54(t,J=1.4Hz,1H),3.30(s,6H),2.45–2.36(m,1H),2.22(d,J=1.4Hz,3H), 1.29–1.08(m,2H),0.90(dd,J=4.7,2.8Hz,2H).
LCMS m/z=409[M+1] +
Example 19N-cyclopropyl-3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] benzamide
Prepared according to the method of example 10 by replacing 3- (phenylcarbamoyl) phenylboronic acid in step e) with 3- (cyclopropylcarbamoyl) phenylboronic acid.
1 H NMR(400MHz,DMSO-d 6 )δ8.48(d,J=4.4Hz,1H),7.86(m,1H),7.72(t,J=2.0Hz,1H),7.54(t,J =7.8Hz,1H),7.42(m,1H),3.29(s,6H),2.86(m,1H),2.45–2.40(m,1H),1.21–1.16(m,2H),0.91–0.86(m, 2H),0.69(m,2H),0.59–0.54(m,2H).
LCMS m/z=396[M+1] +
Example 20 2-cyclopropyl-7- (dimethylamino) -4- {3- [ (2-fluorophenyl) methoxy ] phenyl } - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of 2-cyclopropyl-7- (dimethylamino) -4- {3- [ (2-fluorophenyl) methoxy ] phenyl } - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
2-cyclopropyl-7- (dimethylamino) -4- (3-hydroxyphenyl) - [1,3]Thiazolo [4,5-d]Pyrimidine-5-one (20 mg), 1- (bromomethyl) -2-fluorobenzene (12.66 mg), potassium carbonate (16.83 mg) and acetonitrile (2 mL) were added to a reaction flask, and the reaction system was stirred under nitrogen at 82℃for 2 hours, and the title compound 10.9mg was purified by pre-HPLC as follows (column: YMC-actual Triart C18, 30X 150 mm,5 μm; mobile phase A: water (10 mmol/LNH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 15%B to 42%B in 8min,42%B; the wavelength is UV 220nm; RT1 (min) 7.52; column temperature 25 deg.c).
1 H NMR(400MHz,DMSO-d 6 )δ7.58(m,1H),7.47–7.34(m,2H),7.29–7.21(m,2H),7.07(m,1H),7.00 –6.92(m,1H),6.86(m,1H),5.13(s,2H),3.28(s,6H),2.42(d,J=4.8Hz,1H),1.19(m,2H),0.94–0.87(m, 2H).
LCMS m/z=437[M+1] +
Example 21 2-cyclopropyl-7- (dimethylamino) -4- {3- [ (4-fluorophenyl) methoxy ] phenyl } - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 20 by replacing 1- (bromomethyl) -2-fluorobenzene in step a) with 1- (bromomethyl) -4-fluorobenzene.
1 H NMR(400MHz,DMSO-d 6 )δ7.54–7.49(m,2H),7.37(t,J=8.0Hz,1H),7.26–7.19(m,2H),7.05(m, 1H),6.93(t,J=2.4Hz,1H),6.84(m,1H),5.08(s,2H),3.29(s,6H),2.43–2.39(m,1H),1.22–1.16(m,2H), 0.91–0.86(m,2H).
LCMS m/z=437[M+1] +
EXAMPLE 22 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -N- (2, 2-trifluoroethyl) benzamide
a) 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3]Thiazolo [4,5-d]Pyrimidin-4-yl]Preparation of N- (2, 2-trifluoroethyl) benzamide 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3]]Thiazolo [4,5-d]Pyrimidin-4-yl]Benzoic acid solution (30 mg), 2-trifluoroethylamine (11.67 mg), TBTU (35.14 mg), N-diisopropylethylamine (38.08 mg), dichloromethane (1.5 mL) were added to a reaction flask and stirred at room temperature under nitrogen for 1 hour, and the title compound 6.5mg was purified by preparative HPLC under the following conditions (Column: XBridge Prep OBD C Column,30 x 150mm,5 μm; mobile phase A: water (10 mmol/LNH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 10%B to 55%B in 8min,55%B; the wavelength is UV 220nm; RT1 (min) 6.98; column temperature 25 deg.c).
1 H NMR(400MHz,DMSO-d 6 )δ9.15(t,J=6.0Hz,1H),7.94(m,1H),7.82(t,J=2.0Hz,1H),7.61(t,J= 7.8Hz,1H),7.51(m,1H),4.09(m,2H),3.31(s,6H),2.44–2.40(m,1H),1.18(m,2H),0.94–0.84(m,2H).
LCMS m/z=438[M+1] +
Example 23 2-cyclopropyl-7- (dimethylamino) -4- [3- (hydroxymethyl) phenyl ] - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of [ (3-bromophenyl) methoxy ] (tert-butyl) dimethylsilane
(3-bromophenyl) methanol (10 g), t-butyldimethylchlorosilane (9.67 g), triethylamine (16.23 g), and methylene chloride (100 mL) were added to a reaction flask, stirred at room temperature under a nitrogen atmosphere for 1 hour, concentrated under reduced pressure, and the residue was evaporated to dryness and purified by column chromatography (mobile phase: petroleum ether/ethyl acetate=20/3 (V/V)) to give 14g of the title compound.
b) Preparation of 3- { [ (tert-butyldimethylsilyl) oxy ] methyl } phenylboronic acid
[ (3-bromophenyl) methoxy ] (tert-butyl) dimethylsilane (2 g) was dissolved in tetrahydrofuran (40 mL), n-butyllithium (0.64 g) was added dropwise under nitrogen atmosphere at-78℃and stirred for 30 minutes, then trimethyl borate (1.03 g) was added, stirred at room temperature for 2 hours, water (40 mL) was added at 0℃to quench the reaction, extraction was performed with ethyl acetate (3X 40 mL), the combined organic layers were washed with saturated brine (1X 40 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by reverse flash chromatography under the following conditions: xselect CSH OBD Column 30 x 150mm 5 μm; mobile phase A water (10 MMOL/LNH4HCO 3), mobile phase B acetonitrile; the flow rate is 1 mL/min; gradient 10%B to 40%B in 8min,40%B; the wavelength is 220nm, and the chromatographic column temperature is 25 ℃ to obtain 500mg of the title compound.
c) Preparation of 4- (3- { [ (tert-butyldimethylsilyl) oxy ] methyl } phenyl) -2-cyclopropyl-7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 10 by replacing 3- (phenylcarbamoyl) phenylboronic acid in step e) with 3- { [ (tert-butyldimethylsilyl) oxy ] methyl } phenylboronic acid.
d) Preparation of 2-cyclopropyl-7- (dimethylamino) -4- [3- (hydroxymethyl) phenyl ] - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
2-cyclopropyl-7- (dimethylamino) -4- [3- (hydroxymethyl) phenyl ]]-[1,3]Thiazolo [4,5-d]Pyrimidin-5-one (2)10 mg) was dissolved in tetrahydrofuran (2 mL), tetrabutylammonium fluoride (120.23 mg) was added, and the reaction system was stirred at room temperature under nitrogen for 0.5 hour, and purified by Prep-HPLC to give the title compound 12.2mg under the following conditions (Column: XBridge Prep OBD C Column,30 x 150mm,5 μm; mobile phase A water (10 mmol/L NH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 5%B to 40%B in 8min; the wavelength is UV220 nm; RT1 (min) 7.18; column temperature 25 deg.c).
1 H NMR(400MHz,DMSO-d 6 )7.41(m,1H),7.33(m,1H),7.18(s,1H),7.11(m,1H),5.29(t,J=5.8 Hz,1H),4.54(d,J=5.0Hz,2H),3.31(m,6H),2.40(m,1H),1.19(m,2H),0.89(m,2H).
LCMS m/z=343[M+1] +
Example 24 2-cyclopropyl-7- (dimethylamino) -4- [3- (pyridin-2-ylmethoxy) phenyl ] - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 20 by replacing 1- (bromomethyl) -2-fluorobenzene in step a) with 2- (bromomethyl) pyridine.
1 H NMR(400MHz,DMSO-d 6 )δ8.58(m,1H),7.85(m,1H),7.55(m,1H),7.40–7.33(m,2H),7.07(m, 1H),6.97–6.94(m,1H),6.86(m,1H),5.18(s,2H),3.29(s,6H),2.41(m,1H),1.22–1.16(m,2H),0.91–0.86 (m,2H).
LCMS m/z=420[M+1] +
Example 25 2-cyclopropyl-7- (dimethylamino) -4- (3- (pyridin-3-ylmethoxy) phenyl) thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 20 by replacing 1- (bromomethyl) -2-fluorobenzene in step a) with 3- (bromomethyl) pyridine.
1 H NMR(400MHz,DMSO-d 6 )δ8.68(s,1H),8.56(d,J=4.0Hz,1H),7.89(dt,J=7.9,1.9Hz,1H),7.46 –7.41(m,1H),7.38(d,J=8.0Hz,1H),7.10–7.05(m,1H),6.97(t,J=2.2Hz,1H),6.89–6.84(m,1H),5.16 (s,2H),3.30(s,6H),2.42(d,J=4.5Hz,1H),1.19(dt,J=8.1,3.5Hz,2H),0.92–0.86(m,2H).
LCMS m/z=420[M+1] +
EXAMPLE 26 2-cyclopropyl-7- (dimethylamino) -4- [3- (pyridin-4-ylmethoxy) phenyl ] - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 20 by replacing 1- (bromomethyl) -2-fluorobenzene in step a) with 4- (bromomethyl) pyridine.
1 H NMR(400MHz,DMSO-d 6 )δ8.51(d,J=5.2Hz,2H),7.40–7.30(m,3H),7.00(dd,J=8.3,2.6Hz, 1H),6.89(d,J=2.3Hz,1H),6.80(dd,J=7.7,1.8Hz,1H),5.12(s,2H),3.22(s,6H),2.33(dq,J=8.5,4.7,4.3 Hz,1H),1.15–1.09(m,2H),0.84–0.79(m,2H).
LCMS m/z=420[M+1] +
EXAMPLE 27 2-cyclopropyl-7- (dimethylamino) -4- {3- [ (4-methyl-1, 3-oxazol-2-yl) amino ] phenyl } - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method described in example 13, substituting 4-methyl-1, 3-oxazol-2-amine for 2-aminobenzoxazole in step b).
1 H NMR(400MHz,DMSO-d 6 )δ10.12(s,1H),7.66–7.47(m,2H),7.43–7.23(m,2H),6.86–6.60(m, 1H),3.31(s,6H),2.41(dq,J=8.5,4.9,4.2Hz,1H),2.02(d,J=1.4Hz,3H),1.22–1.10(m,2H),0.96–0.86 (m,2H).
LCMS m/z=409[M+1] +
EXAMPLE 28 4- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -2-phenyl-3H-isoindol-1-one
Prepared according to the method of example 10 by substituting 2-cyclopropyl-7- (dimethylamino) -4H- [1,3] thiazolo [4,5-d ] pyrimidin-5-one in step e) with 4- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -2, 3-dihydro-isoindol-1-one and 3- (phenylcarbamoyl) phenylboronic acid.
1 H NMR(400MHz,DMSO-d 6 )δ7.87(m,3H),7.71–7.59(m,2H),7.45–7.35(m,2H),7.17(t,J=7.3 Hz,1H),4.78(s,2H),3.33(m,6H),2.45–2.40(m,1H),1.29–1.10(m,2H),0.95–0.79(m,2H).
LCMS m/z=444[M+1] +
Example 29 2-cyclopropyl-7- (dimethylamino) -4- {3- [ (3-fluorophenyl) methoxy ] phenyl } - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 20 by replacing 1- (bromomethyl) -2-fluorobenzene in step a) with 1- (bromomethyl) -3-fluorobenzene.
1 H NMR(400MHz,DMSO-d 6 )δ7.44(m,1H),7.38(t,J=8.0Hz,1H),7.30(m,2H),7.20–7.13(m,1H), 7.06(m,1H),6.94(t,J=2.4Hz,1H),6.85(m,1H),5.13(s,2H),3.29(s,6H),2.41(m,1H),1.22–1.16(m,2H), 0.91–0.84(m,2H).
LCMS m/z=487[M+1] +
Example 30 4- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -2, 3-dihydro-isoindol-1-one
Prepared according to the method of example 10 by replacing 3- (phenylcarbamoyl) phenylboronic acid in step e) with 4- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -2, 3-dihydro-isoindol-1-one.
1 H NMR(400MHz,DMSO-d 6 )δ8.56(s,1H),7.73(m,1H),7.60(m,1H),7.51(m,1H),4.17(d,J=17.7 Hz,1H),4.05(d,J=17.7Hz,1H),2.46(m,3H),2.45–2.42(m,3H),2.40(m,1H),1.27–1.13(m,2H),0.96– 0.80(m,2H).
LCMS m/z=368[M+1] +
Example 31 4- [3- (1, 3-Benzooxazol-2-yloxy) phenyl ] -2-cyclopropyl-7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 20 by replacing 1- (bromomethyl) -2-fluorobenzene in step a) with 2-chlorobenzoxazole.
1 H NMR(400MHz,DMSO-d 6 )δ7.67–7.62(m,1H),7.62–7.58(m,2H),7.56–7.52(m,2H),7.34–7.29 (m,3H),3.32(s,6H),2.47–2.40(m,1H),1.20(dt,J=8.2,3.5Hz,2H),0.99–0.93(m,2H).
LCMS m/z=446[M+1] +
Example 32 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -N-methyl-N- (2, 2-trifluoroethyl) benzamide
a) Preparation of methyl 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] benzoate
Prepared according to the method of example 10 by replacing 3- (phenylcarbamoyl) phenylboronic acid in step e) with 3- (methoxycarbonyl) phenylboronic acid.
b) Preparation of 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] benzoic acid
Methyl 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] benzoate (200 mg), lithium hydroxide (38.79 mg), tetrahydrofuran (10 mL) were added to a reaction flask, the reaction was stirred at 25 ℃ for 1 hour, and the reaction solution was purified by reverse flash chromatography under the following conditions to give 180mg of the title compound: a chromatographic Column XBridge Prep OBD C Column,30 x 150mm,5 μm; mobile phase A is water (10 mmol/L NH4HCO 3), mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 20%B to 55%B in 8min,55%B; the wavelength is UV220 nm; the column temperature was 25 ℃.
c) Preparation of 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -N-methyl-N- (2, 2-trifluoroethyl) benzamide
3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3]Thiazolo [4,5-d]Pyrimidin-4-yl]Benzoic acid (50 mg), oxalyl chloride (35.61 mg) and dichloromethane (1 mL) were added to a reaction flask, then N, N-dimethylformamide (0.01 mL) was added, the reaction was stirred at 25 ℃ for 1 hour, the reaction solution was concentrated under reduced pressure, dissolved with tetrahydrofuran, and the reaction solution was alkalified to ph=8 with N, N-diisopropylethylamine, methyl (2, 2-trifluoroethyl) amine (23.80 mg) was added, stirred at 25 ℃ for 2 hours, and the title compound 9.6mg was purified by Prep-HPLC under the following purification conditions: (chromatographic Column: XBridge Prep OBD C Column, 30X 150mm,5 μm; mobile phase A: water (10 mmol/LNH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 20%B to 50%B in 8min,50%B; the wavelength is UV 220nm; RT1 (min) 6.80; column temperature 25 deg.c).
1 H NMR(400MHz,DMSO-d 6 )δ7.57(t,J=7.8Hz,1H),7.50–7.30(m,3H),4.36(d,J=5.6Hz,2H), 3.07(s,3H),2.49(d,J=2.0Hz,6H),2.46–2.37(m,1H),1.21–1.13(m,2H),0.93–0.82(m,2H).
LCMS m/z=452[M+1] +
Example 33 2-cyclopropyl-7- (dimethylamino) -4- [3- (2-fluorophenoxymethyl) phenyl ] - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of methyl {3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] phenyl } methanesulfonate
2-cyclopropyl-7- (dimethylamino) -4- [3- (hydroxymethyl) phenyl ] - [1,3] thiazolo [4,5-d ] pyrimidin-5-one solution (50 mg), triethylamine (59.10 mg) were dissolved in tetrahydrofuran (1 mL), methanesulfonyl chloride (33.45 mg) was added under ice bath, the reaction was stirred at room temperature for 4 hours under nitrogen atmosphere, the reaction was quenched with water (1 mL) at room temperature, extracted with ethyl acetate (3×1 mL), and the combined organic layers were washed with saturated brine (2 mL) and concentrated under reduced pressure to give 50mg of the title compound.
b) Preparation of 2-cyclopropyl-7- (dimethylamino) -4- [3- (2-fluorophenoxymethyl) phenyl ] - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Sodium hydride (5.71 mg) was added to a solution of o-fluorophenol (26.66 mg) in N, N-dimethylformamide (1 mL) under nitrogen with stirring for 30 min, and {3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3 ]Thiazolo [4,5-d]Pyrimidin-4-yl]Phenyl } methanesulfonate (50 mg), the reaction was stirred at room temperature for 4 hours, filtered, the filter cake was washed with N, N-dimethylformamide (1X 1 mL), the filtrate was concentrated under reduced pressure, and the title compound 5.8mg was obtained by preparative HPLC as follows: (chromatographic column: YMC-actual Triart C18,30 x 150mm,5 μm; mobile phase A: water (10 mmol/LNH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 30%B to 65%B in 8min, 65% B; the wavelength is UV 220nm; RT1 (min) 8.07; column temperature 25 deg.c).
1 H NMR(400MHz,DMSO-d 6 )δ7.55–7.46(m,2H),7.39–7.17(m,4H),7.16–6.90(m,2H),5.21(s, 2H),3.30-3.27(m,6H),2.41(m,1H),1.27–1.08(m,2H),0.96–0.79(m,2H).
LCMS m/z=437[M+1] +
Example 34 2-cyclopropyl-7- (dimethylamino) -4- [3- (3-fluorophenoxymethyl) phenyl ] - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 33, by replacing the o-fluorophenol in step b) with m-fluorophenol.
1 H NMR(400MHz,DMSO-d 6 )δ7.53–7.45(m,2H),7.36(m,1H),7.31(m,1H),7.25(m,1H),6.96– 6.85(m,2H),6.82–6.74(m,1H),5.16(s,2H),3.30-3.27(m,6H),2.41(m,1H),1.28–1.09(m,2H),0.96– 0.81(m,2H).
LCMS m/z=437[M+1] +
Example 35 2-cyclopropyl-7- (dimethylamino) -4- [3- (4-fluorophenoxymethyl) phenyl ] - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 33, by replacing the o-fluorophenol of step b) with p-fluorophenol.
1 H NMR(400MHz,DMSO-d 6 )δ7.56–7.46(m,2H),7.38(S,1H),7.27(m,1H),7.18–7.09(m,2H), 7.08–6.99(m,2H),5.13(s,2H),3.34(s,6H),2.42(m,1H),1.30–1.14(m,2H),1.00–0.81(m,2H).
LCMS m/z=437[M+1] +
Example 36 2-benzyl-4- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -3H-isoindol-1-one
a) Preparation of 2-benzyl-4- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -3H-isoindol-1-one
Sodium hydride (2.61 mg) was added to a solution of benzyl bromide (18.62 mg) in N, N-dimethylformamide (1 mL) under nitrogen with stirring for 30 min, and 4- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3]Thiazolo [4,5-d]Pyrimidin-4-yl]-2, 3-dihydro-isoindol-1-one (20 mg), the reaction stirred at room temperature for 2 hours, filtered, the filter cake washed with N, N-dimethylformamide (1 x1 mL), the filtrate concentrated under reduced pressure and purified by preparative HPLC to give the title compound 6.8mg, purification method as follows: (chromatographic Column: XBridge Prep OBD C Column, 30X 150mm,5 μm; mobile phase A: water (10 mmol/LNH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 15%B to 62%B in 8min,62%B; the wavelength is UV 220nm; RT1 (min) 9.02; column temperature 25 deg.c).
1 H NMR(400MHz,DMSO-d 6 )δ7.80(m,1H),7.63(t,J=7.7Hz,1H),7.53(m,1H),7.34(m,2H), 7.31–7.20(m,3H),4.69(s,2H),4.25–3.96(m,2H),3.32(m,6H),2.38(m,1H),1.20–1.06(m,2H),0.91 –0.69(m,2H).
LCMS m/z=458[M+1] +
Example 37 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -N- (3-fluorophenyl) benzamide
Prepared according to the method of example 32 by replacing the methyl (2, 2-trifluoroethyl) amine of step c) with 3-fluoroaniline.
1 H NMR(400MHz,DMSO-d 6 )δ10.47(s,1H),8.01(dt,J=7.9,1.4Hz,1H),7.88(t,J=1.9Hz,1H),7.75 (dt,J=11.7,2.3Hz,1H),7.65(t,J=7.8Hz,1H),7.61–7.48(m,2H),7.39(td,J=8.2,6.7Hz,1H),6.94(td,J =8.5,2.6Hz,1H),3.31(s,6H),2.44(dt,J=9.0,4.7Hz,1H),1.26–1.08(m,2H),0.98–0.81(m,2H).
LCMS m/z=450[M+1] +
EXAMPLE 38 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -N- (2-fluorophenyl) benzamide
Prepared according to the method of example 32 by replacing the methyl (2, 2-trifluoroethyl) amine of step c) with 2-fluoroaniline.
1 H NMR(400MHz,DMSO-d 6 )δ10.18(s,1H),8.03(dt,J=8.0,1.3Hz,1H),7.91(t,J=1.9Hz,1H),7.64 (t,J=7.9Hz,1H),7.59(td,J=7.9,1.5Hz,1H),7.53(ddd,J=7.9,2.0,1.1Hz,1H),7.32–7.26(m,2H),7.26– 7.19(m,1H),3.31(s,6H),2.47–2.40(m,1H),1.23–1.16(m,2H),0.96–0.88(m,2H).
LCMS m/z=450[M+1] +
Example 39 4- [3- (1, 3-Benzooxazol-2-yloxy) phenyl ] -2-cyclopropyl-7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 32 by replacing methyl (2, 2-trifluoroethyl) amine in step c) with 4-fluorobenzylamine.
1 H NMR(400MHz,DMSO-d 6 )δ9.10(t,J=6.0Hz,1H),7.93(dt,J=7.9,1.4Hz,1H),7.80(t,J=1.9Hz, 1H),7.58(t,J=7.8Hz,1H),7.46(ddd,J=7.8,2.1,1.1Hz,1H),7.41–7.30(m,2H),7.22–7.07(m,2H),4.46 (d,J=5.9Hz,2H),3.30(s,6H),2.42(td,J=8.2,4.3Hz,1H),1.23–1.11(m,2H),0.97–0.80(m,2H).
LCMS m/z=464[M+1] +
EXAMPLE 40 1- {3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] phenyl } -3-phenylimidazolin-2-one
a) Preparation of 1- {3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] phenyl } -3-phenylimidazolin-2-one
4- (3-bromophenyl) -2-cyclopropyl-7- (dimethylamino) - [1,3]Thiazolo [4,5-d]Pyrimidine-5-one (30 mg), 1-phenylimidazolin-2-one (18.7 mg), potassium phosphate (32.7 mg), cuprous iodide (2.9 mg), N' -dimethylethylenediamine (1.4 mg) were added to N, N-dimethylformamide (1 mL), stirred at 130℃under a reaction nitrogen atmosphere for 5 hours, filtered, the filter cake was washed with N, N-dimethylformamide (3X 1 mL), and the filtrate was concentrated under reduced pressure to give 15mg of the title compound by preparative HPLC purification under the following conditions: (chromatographic Column: XBridge Prep OBD C Column, 30X 150 mm,5 μm; mobile phase A: water (10 mmol/LNH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 20%B to 55%B in 8min,55%B; the wavelength is UV 220nm; RT1 (min) 8.12; column temperature 25 deg.c).
1 H NMR(400MHz,DMSO-d 6 )δ7.67–7.55(m,4H),7.50–7.31(m,3H),7.11–6.92(m,2H),3.98(s,4H), 3.30(s,6H),2.43(ddd,J=8.2,4.7,3.4Hz,1H),1.19(dt,J=8.2,3.5Hz,2H),0.96–0.89(m,2H).
LCMS m/z=473[M+1] +
EXAMPLE 41 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -N- (4-fluorophenyl) benzamide
Prepared according to the method of example 32 by replacing the methyl (2, 2-trifluoroethyl) amine of step c) with 4-fluoroaniline.
1 H NMR(400MHz,DMSO-d 6 )δ10.36(s,1H),8.02(d,J=7.8Hz,1H),7.88(t,J=1.9Hz,1H),7.84– 7.72(m,2H),7.65(t,J=7.9Hz,1H),7.58–7.47(m,1H),7.20(t,J=8.9Hz,2H),3.33(s,6H),2.44(td,J=8.5, 4.2Hz,1H),1.25–1.14(m,2H),0.98–0.81(m,2H).
LCMS m/z=450[M+1] +
Example 42 4- [3- (1, 3-Benzooxazol-2-yl) phenyl ] -2-cyclopropyl-7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of 4- [3- (1, 3-benzoxazol-2-yl) phenyl ] -2-cyclopropyl-7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
4- (3-bromophenyl) -2-cyclopropyl-7- (dimethylamino) - [1,3]Thiazolo [4,5-d]Pyrimidine-5-one (45 mg), benzoxazole (23.29 mg), cuprous bromide (4.95 mg), cesium carbonate (112.41 mg), [1,1' -bis (di-t-butylphosphine) ferrocene]Palladium (II) dichloride (7.50 mg) and N, N-dimethylformamide (1 mL) were added to a reaction flask, and the reaction system was stirred at 130℃for 1 hour under a nitrogen atmosphere, and the title compound 14.4mg was obtained by separation and purification by preparative HPLC under the following purification conditions: (chromatographic Column: XBridge Prep OBD C Column, 30X 150mm,5 μm; mobile phase A: water (10 mmol/LNH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 20%B to 50%B in 8min,55%B; the wavelength is UV220 nm; column temperature 25 deg.c).
1 H NMR(400MHz,DMSO-d 6 )δ8.23(dt,J=7.9,1.3Hz,1H),8.11(t,J=1.9Hz,1H),7.85–7.78(m,2H), 7.73(t,J=7.9Hz,1H),7.60–7.56(m,1H),7.45(tt,J=7.4,5.8Hz,2H),3.32(s,6H),2.45–2.41(m,1H),1.21 –1.15(m,2H),0.93–0.88(m,2H).
LCMS m/z=430[M+1] +
EXAMPLE 43 2-cyclopropyl-4- (3-cyclopropylphenyl) -7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of 2-cyclopropyl-4- (3-cyclopropylphenyl) -7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
4- (3-bromophenyl) -2-cyclopropyl-7- (dimethylamino) - [1,3]Thiazolo [4,5-d]Pyrimidine-5-one (50 mg), cyclopropylboronic acid (21.95 mg),Potassium phosphate (81.37 mg), palladium acetate (2.90 mg), tricyclohexylphosphine (3.58 mg), toluene (1 mL) and water (0.1 mL) were added to a reaction flask, and the mixture was stirred at 80℃for 2 hours under a nitrogen atmosphere, and the reaction solution was concentrated under reduced pressure and purified by preparative HPLC to give the title compound 4.1mg under the following purification conditions: (chromatographic Column: XBridge Prep OBD C Column, 30X 150mm,5 μm; mobile phase A: water (10 mmol/L NH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 20%B to 53%B in 8min,53%B; the wavelength is UV 220nm; RT1 (min) 7.72; column temperature 25 deg.c).
1 H NMR(400MHz,DMSO-d 6 )δ7.32(t,J=7.8Hz,1H),7.08(dt,J=7.8,1.4Hz,1H),7.01(ddd,J=7.8, 2.1,1.1Hz,1H),6.96(t,J=1.9Hz,1H),3.29(s,6H),2.42(ddd,J=8.1,4.7,3.4Hz,1H),1.95(tt,J=8.4,5.1 Hz,1H),1.18(dt,J=8.2,3.5Hz,2H),1.03–0.93(m,2H),0.92–0.82(m,2H),0.73–0.57(m,2H).
LCMS m/z=353[M+1] +
EXAMPLE 44 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -N- (2, 3, 6-trifluorophenyl) benzamide
Prepared according to the method of example 32 by replacing the methyl (2, 2-trifluoroethyl) amine of step c) with 2,3, 6-trifluoroaniline.
1 H NMR(400MHz,DMSO-d 6 )δ10.42(s,1H),8.18–7.97(m,1H),7.92(s,1H),7.67(t,J=8.2Hz,1H), 7.57(d,J=8.2Hz,1H),7.52(s,1H),7.29(s,1H),3.31(s,6H),2.33(s,1H),1.20(d,J=8.1Hz,2H),0.91(d,J =4.9Hz,2H).
LCMS m/z=486[M+1] +
Example 45 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -N- (2, 6-difluorophenyl) benzamide
Prepared according to the method of example 32 by replacing the methyl (2, 2-trifluoroethyl) amine of step c) with 2, 6-difluoroaniline.
1 H NMR(400MHz,DMSO-d 6 )δ10.24(s,1H),8.07(dt,J=7.8,1.4Hz,1H),7.94(t,J=1.9Hz,1H),7.68 (t,J=7.9Hz,1H),7.58(ddd,J=7.9,2.1,1.1Hz,1H),7.49–7.35(m,1H),7.24(q,J=8.4Hz,2H),3.35(s, 6H),2.46(dd,J=8.2,4.7Hz,1H),1.21(dt,J=8.3,3.6Hz,2H),0.96–0.87(m,2H).
LCMS m/z=468[M+1] +
Example 46 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -N- (2, 5-difluorophenyl) benzamide
Prepared according to the method of example 32 by replacing the methyl (2, 2-trifluoroethyl) amine of step c) with 2, 5-difluoroaniline.
1 H NMR(400MHz,DMSO-d 6 )δ10.28(s,1H),8.02(dt,J=7.9,1.3Hz,1H),7.90(t,J=1.9Hz,1H),7.65 (t,J=7.8Hz,1H),7.61–7.45(m,2H),7.36(ddd,J=10.0,9.1,5.1Hz,1H),7.13(ddt,J=7.9,5.8,4.0Hz,1H), 3.31(s,6H),2.47–2.38(m,1H),1.27–1.13(m,2H),0.96–0.85(m,2H).
LCMS m/z=468[M+1] +
Example 47 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] -N- (2-fluorophenyl) -N-methylbenzamide
Prepared according to the method of example 32 by replacing the methyl (2, 2-trifluoroethyl) amine of step c) with 2-fluoro-N-methylaniline.
1 H NMR(400MHz,DMSO-d 6 )δ7.44(t,J=8.0Hz,1H),7.37–7.09(m,7H),3.29(s,6H),2.49(s,3H), 2.40(tt,J=8.1,4.7Hz,1H),1.26–1.16(m,2H),0.95–0.85(m,2H)
LCMS m/z=464[M+1] +
EXAMPLE 48 2-cyclopropyl-7- (dimethylamino) -4- (pyridin-3-yl) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 10 by replacing 3- (phenylcarbamoyl) phenylboronic acid in step e) with pyridin-3-ylboronic acid.
1 H NMR(400MHz,DMSO-d 6 )δ8.62(s,2H),7.78(d,J=8.0Hz,1H),7.56(s,1H),3.30(s,6H),2.44(dd, J=8.5,4.1Hz,1H),1.19(dq,J=7.1,4.1Hz,2H),0.98–0.84(m,2H).
LCMS m/z=314[M+1] +
Example 49 4-chloro-N-cyclopropyl-3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] benzamide
Prepared according to the method of example 10 by replacing 3- (phenylcarbamoyl) phenylboronic acid in step e) with 2-chloro-5- (cyclopropylcarbamoyl) phenylboronic acid.
1 H NMR(400MHz,DMSO-d 6 )δ8.59(d,J=4.5Hz,1H),7.56(d,J=8.5Hz,1H),7.36(dd,J=8.5,2.5 Hz,1H),7.33(d,J=2.5Hz,1H),3.31(s,6H),2.81(td,J=7.4,3.7Hz,1H),2.43(dq,J=8.2,4.3,3.7Hz,1H), 1.21(td,J=7.3,4.2Hz,2H),1.03–0.82(m,2H),0.67(dt,J=6.9,3.3Hz,2H),0.58–0.48(m,2H).
LCMS m/z=430[M+1] +
Example 50 2-cyclopropyl-4- [3- (5-cyclopropyl-1, 3, 4-oxadiazol-2-yl) phenyl ] -7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of 2-cyclopropyl-1, 3, 4-oxadiazole
Cyclopropanecarbohydrazide (10 g), p-toluenesulfonic acid (50 mg), trimethyl orthoformate (15.90 g) were added to a reaction flask, stirred overnight at 110℃under nitrogen atmosphere, distilled under reduced pressure, and a fraction at 50-80℃was collected to give 8g of the title compound.
b) Preparation of 2-cyclopropyl-4- [3- (5-cyclopropyl-1, 3, 4-oxadiazol-2-yl) phenyl ] -7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one by the method of preparation according to example 42, the benzoxazole in step a) was replaced by 2-cyclopropyl-1, 3, 4-oxadiazole.
1 H NMR(400MHz,DMSO-d 6 )δ7.98(m,1H),7.87(t,J=2.0Hz,1H),7.68(t,J=8.0Hz,1H),7.53(m, 1H),7.08(s,2H),2.48(m,2H),2.42(m,2H),2.37–2.24(m,2H),1.20–1.12(s,6H),0.92–0.87(m,2H). LCMS m/z=421[M+1] +
Example 51 2-cyclopropyl-4- [3- (5-cyclopropyl-1, 3, 4-oxadiazol-2-yl) phenyl ] -7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] benzaldehyde
Prepared according to the method of example 10 by replacing 3- (phenylcarbamoyl) phenylboronic acid in step e) with 3-formylphenylboronic acid.
b) Preparation of N' - [ (1E) - {3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] phenyl } methylene ] -4-methylbenzenesulfonyl hydrazide
TsNHNH 2 (109.42 mg) was dissolved in methanol (1 mL) at room temperature under nitrogen, and 3- [ 2-cyclopropane was added1, 3-hydroxy-7- (dimethylamino) -5-oxo-1]Thiazolo [4,5-d]Pyrimidin-4-yl]Benzaldehyde (200 mg) was stirred at room temperature for 1 hour, and the precipitated solid was collected by filtration and washed with methanol (1×1 mL) to give the title compound 190mg.
c) Preparation of 2-cyclopropyl-4- [3- (5-cyclopropyl-1, 3, 4-oxadiazol-2-yl) phenyl ] -7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
N' - [ (1E) - {3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3]Thiazolo [4,5-d]Pyrimidin-4-yl]Phenyl } methylene]4-Methylbenzenesulfonyl hydrazide (50 mg), cyclopropylboronic acid (12.7 mg), potassium carbonate (40.8 mg), 1, 4-dioxane (0.5 mL) were added to the reaction flask, and reacted at 110℃for 2 hours under a nitrogen atmosphere to give the title compound 10.5mg by preparative HPLC under the following conditions: (Column temperature: XBridge Prep OBD C Column,30 x 150mm,5um; mobile phase A: water (10 mmol/LNH) 4 HCO 3 ) Mobile phase B is acetonitrile; the flow rate is 1mL/min; gradient 10%B to 67%B in 10min,67%B; the wavelength is UV 220nm; RT1 (min) 9.13; column temperature 25 deg.c).
1 H NMR(400MHz,DMSO-d 6 )(400MHz,DMSO-d 6 ,ppm):δ7.37(m,1H),7.28(m,1H),7.13(s,1H), 7.08(m,1H),3.29(s,6H),2.56(m,2H),2.41(m,1H),1.18(m,2H),1.03–0.95(m,1H),0.93–0.84(m, 2H),0.55–0.40(m,2H),0.31–0.15(m,2H).
LCMS m/z=367[M+1] +
Example 52 2-cyclopropyl-4- [3- (5-cyclopropyl-1, 3, 4-oxadiazol-2-yl) phenyl ] -7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of ethyl 2-oxo-2- (pyridin-2-yl) acetate
2-bromo-1- (pyridin-2-yl) ethanone hydrobromide (5 g), sodium acetate (4.1 g), ethanol (150 mL) were added to the reaction flask and stirred at 80℃for 2 hours, the reaction mixture was cooled to room temperature, filtered, the filtrate was washed with dichloromethane and concentrated under reduced pressure to give the title compound 6.2g.
b) Preparation of 2-hydroxy-1- (pyridin-2-yl) ethanone
Ethyl 2-oxo-2- (pyridin-2-yl) acetate (4.5 g) was dissolved in hydrogen chloride (6 m 125 ml), heated to 50 ℃ and stirred for 1.5h, the reaction was neutralized to pH7 with aqueous sodium bicarbonate, extracted with ethyl acetate (100 ml x 3), the combined organic layers were dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated under reduced pressure to give the title compound 2g.
c) Preparation of 4- (pyridin-2-yl) -1, 3-oxazol-2-amine
2-hydroxy-1- (pyridin-2-yl) ethanone (2 g) was dissolved in 95% ethanol (25 mL), cyanamide (0.92 g) was added, heated under reflux for 14 hours, after the reaction solution was cooled to room temperature, the pH was adjusted to 10 using 1M aqueous sodium hydroxide solution, the aqueous phase was extracted with ethyl acetate (3×40 mL), the combined organic phases were dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the evaporated residue was purified by column chromatography (mobile phase: dichloromethane/methanol=20/1 (V/V)) to give 300mg of the title compound.
d) Preparation of 2-cyclopropyl-4- [3- (5-cyclopropyl-1, 3, 4-oxadiazol-2-yl) phenyl ] -7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one by the method of preparation according to example 13, the 2-aminobenzooxazol in step b) was replaced by 4- (pyridin-2-yl) -1, 3-oxazol-2-amine.
1 H NMR(400MHz,DMSO-d 6 )(400MHz,DMSO-d 6 ,ppm):δ10.68(s,1H),8.55(ddd,J=4.8,1.8,1.0 Hz,1H),7.85(td,J=7.8,1.8Hz,1H),7.64–7.60(m,2H),7.59(s,1H),7.57(dt,J=8.0,1.1Hz,1H),7.44– 7.39(m,1H),7.26(ddd,J=7.6,4.8,1.1Hz,1H),6.89–6.84(m,1H),3.31(s,6H),2.43–2.39(m,1H),1.21– 1.16(m,2H),0.94–0.89(m,2H).
LCMS m/z=472[M+1] +
Example 53 4- (3-Benzylphenyl) -2-cyclopropyl-7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 10 by replacing 3- (phenylcarbamoyl) phenylboronic acid in step e) with 3-benzylphenylboronic acid.
1 H NMR(400MHz,DMSO-d 6 )(400MHz,DMSO-d 6 ,ppm):7.40-7.34(m,1H),7.31–7.22(m,5H), 7.22-7.16(m,1H),7.14-7.12(m,1H),7.11-7.06(m,1H),3.98(s,2H),3.30(m,6H),1.25(m,3H),0.84(m,2H). LCMS m/z=403[M+1] +
Example 54 6-cyclopropyl-4- (dimethylamino) -1- (pyridin-3-yl) thieno [3,2-d ] pyrimidin-2-one
Prepared according to the method of example 10 by substituting 2-cyclopropyl-7- (dimethylamino) -4H- [1,3] thiazolo [4,5-d ] pyrimidin-5-one in step e) with 6-cyclopropyl-4- (dimethylamino) -1H-thieno [3,2-d ] pyrimidin-2-one and 3- (phenylcarbamoyl) phenylboronic acid with pyridin-3-ylboronic acid.
1 H NMR(400MHz,DMSO-d 6 )(400MHz,DMSO-d 6 ,ppm):δ8.67(s,1H),8.59–8.48(m,1H),7.81(d,J =8.0Hz,1H),7.59(dd,J=8.2,4.4Hz,1H),6.20(s,1H),3.32(s,6H),2.21(tt,J=8.6,4.9Hz,1H),1.08(td,J =7.0,4.4Hz,2H),0.79–0.71(m,2H).
LCMS m/z=313[M+1] +
Example 55 4- (2-chlorophenyl) -2-cyclopropyl-7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 10 by replacing step e) 3- (phenylcarbamoyl) phenylboronic acid with 2-chlorophenyl boronic acid. Chiral resolution was performed according to the following method (column: CHIRAL ART Cellulose-SB, 2X 25cm,5 μm; mobile phase A: mtBE (0.1% DEA) -HPLC; mobile phase B: meOH-HPLC; flow rate: 20mL/min; gradient: 20%B to 20%B in 11min; wavelength: UV 220/254nm; RT1 (min): 6.01; RT2 (min): 7.51; sample solvent: meOH-HPLC; injection: 1 mL), under specific chromatographic conditions (column: CHIRAL Cellulose SB 4.6.4.6X 100mm,3 μm; mobile phase A: mtBE (0.1% DEA): B: meOH=80:20; flow rate: 1.0mL/min; wavelength: UV254 nm; RT1 (min): 2.459RT2 (min): 3.071; sample solvent: meOH HPLC; injection: 1 mL), retention time 2.459 min: 55A, retention time 3.071 min: 55B.
55A: 1 H NMR(400MHz,Chloroform-d)δ7.62(dt,J=6.0,3.3Hz,1H),7.50–7.44(m,2H),7.44–7.37 (m,1H),3.31(s,6H),2.42(tt,J=8.2,4.8Hz,1H),1.19(ddd,J=8.2,4.2,1.3Hz,2H),0.87(ddd,J=7.8,4.9, 1.4Hz,2H).
55B: 1 H NMR(400MHz,Chloroform-d)δ7.65–7.59(m,1H),7.50–7.44(m,2H),7.44–7.39(m,1H), 3.31(s,6H),2.46–2.38(m,1H),1.24–1.12(m,2H),0.92–0.80(m,2H).
LCMS m/z=347[M+1] +
Example 56 2-cyclopropyl-7- (dimethylamino) -4- (2-ethynylphenyl) thiazolo [4,5-d ] pyrimidin-5 (4H) -one
Prepared according to the method described in example 10, by replacing step e) 3- (phenylcarbamoyl) phenylboronic acid with 2-ethynylphenylboronic acid.
Chiral resolution was performed according to the following method (column: CHIRALART Cellulose-SB, 2X 25cm,5 μm; mobile phase A: mtBE (0.1% DEA) -HPLC, mobile phase B: etOH-HPLC; flow rate: 1mL/min; gradient: 20%B to 20%B in 9.5min; wavelength: UV 220/254nm; RT1 (min): 5.5; RT2 (min): 8.61; sample: meOH-HPLC; injection amount: 1.2 mL), under specific chromatographic conditions (column: CHIRAL Cellulose SB 4.6.4.6X 100mm,3 um; mobile phase: mtBE (0.1% DEA): meOH=80:20; flow rate: 1.0mL/min; wavelength: UV254nm; RT1 (min): 2.230RT2 (min): 3.354; sample S: meOH-HPLC; injection amount: 1 mL), retention time 2.230 min: 56A, retention time 3.354 min: 56B.
56A: 1 HNMR(400MHz,Chloroform-d)δ7.61(dd,J=7.6,1.6Hz,1H),7.52(td,J=7.6,1.6Hz,1H),7.44(td, J=7.6,1.4Hz,1H),7.32(dd,J=7.9,1.3Hz,1H),4.06(s,1H),3.31(s,6H),2.46–2.36(m,1H),1.18(dtd,J= 8.0,4.1,2.8Hz,2H),0.94–0.76(m,2H).
56B: 1 HNMR(400MHz,Chloroform-d)δ7.61(dd,J=7.7,1.6Hz,1H),7.52(td,J=7.7,1.7Hz,1H),7.44(td,J =7.6,1.4Hz,1H),7.32(dd,J=7.8,1.3Hz,1H),4.06(s,1H),3.31(s,6H),2.46–2.37(m,1H),1.18(dtd,J= 8.1,4.1,2.8Hz,2H),0.92–0.81(m,2H).
Example 57 3- [ 6-cyclopropyl-4- (dimethylamino) -2-oxothieno [3,2-d ] pyrimidin-1-yl ] -N- (2-fluorophenyl) -N-methylbenzamide
a) Preparation of 6-bromo-2-chloro-N, N-dimethylthieno [3,2-d ] pyrimidin-4-amine
6-bromo-2, 4-dichlorothieno [3,2-d ] pyrimidine (2 g), dimethylamine (0.64 g), N-diisopropylethylamine (3.64 g), 1, 4-dioxane (15 mL) were added to a reaction flask, the reaction was stirred at room temperature for 2 hours, extracted with ethyl acetate (3X 20 mL), the combined organic layers were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the title compound 2g.
b) Preparation of 6-bromo-4- (dimethylamino) -1H-thieno [3,2-d ] pyrimidin-2-one
6-bromo-2-chloro-N, N-dimethylthieno [3,2-d ] pyrimidin-4-amine (2 g) was dissolved in acetic acid (40 mL), stirred at 100℃for 12 hours, the reaction solution was concentrated under reduced pressure, the mixture was concentrated under reduced pressure and purified by silica gel column chromatography, and the residue was evaporated to dryness and purified by column chromatography (mobile phase: dichloromethane/methanol=20/1 (V/V)), to give the title compound 1.9g.
c) Preparation of 6-cyclopropyl-4- (dimethylamino) -1H-thieno [3,2-d ] pyrimidin-2-one
6-bromo-4- (dimethylamino) -1H-thieno [3,2-d ] pyrimidin-2-one (2 g), cyclopropylboronic acid (1.88 g), palladium acetate (0.33 g), tricyclohexylphosphine (0.41 g), potassium phosphate (6.97 g), toluene (8 mL), water (2 mL) were stirred under nitrogen at 80℃for 2 hours, the reaction solution was concentrated under reduced pressure, and the residue was evaporated to dryness and purified by column chromatography (mobile phase: dichloromethane/methanol=20/1 (V/V)) to give 210mg of the title compound.
d) Preparation of methyl 3- [ 6-cyclopropyl-4- (dimethylamino) -2-oxothieno [3,2-d ] pyrimidin-1-yl ] benzoate
Prepared according to the method described in example 10, by replacing step e) 3- (phenylcarbamoyl) phenylboronic acid with 3- (methoxycarbonyl) phenylboronic acid.
e) Preparation of 3- [ 6-cyclopropyl-4- (dimethylamino) -2-oxothiophen [3,2-d ] pyrimidin-1-yl ] benzoic acid
Prepared according to the method of example 32 by substituting methyl 3- [ 6-cyclopropyl-4- (dimethylamino) -2-oxothieno [3,2-d ] pyrimidin-1-yl ] benzoate for methyl 3- [ 2-cyclopropyl-7- (dimethylamino) -5-oxo- [1,3] thiazolo [4,5-d ] pyrimidin-4-yl ] benzoate of step b).
f) Preparation of 3- [ 6-cyclopropyl-4- (dimethylamino) -2-oxothieno [3,2-d ] pyrimidin-1-yl ] -N- (2-fluorophenyl) -N-methylbenzamide
Prepared according to the method of example 32, replacing step c) methyl (2, 2-trifluoroethyl) amine with 2-fluoro-N-methylaniline.
1 H NMR(400MHz,DMSO-d 6 ,)δ7.43(d,J=15.4Hz,3H),7.34–7.26(m,1H),7.16(td,J=19.9,19.2, 9.4Hz,4H),5.46(s,1H),3.32(s,3H),3.29(s,6H),2.17(tt,J=8.2,4.9Hz,1H),1.21–1.08(m,2H),0.69(dd,J =4.9,2.1Hz,2H).
LCMS m/z=463[M+1] +
Example 58 2-cyclopropyl-4- [3- (1-cyclopropylpyrazol-4-yl) phenyl ] -7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
a) Preparation of 2-cyclopropyl-4- [3- (1-cyclopropylpyrazol-4-yl) phenyl ] -7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
4- (3-bromophenyl) -2-cyclopropyl-7- (dimethylamino) - [1,3] thiazolo [4,5-d ] pyrimidin-5-one (30 mg), 1-cyclopropyl-4- (4, 5-dioxaborolan-2-yl) pyrazole (23.3 mg), sodium carbonate (24.3 mg), ditriphenylphosphine palladium dichloride (5.3 mg), 1, 4-dioxane (3 mL) and water (0.2 mL) were added to the reaction flask, and after stirring at 80℃for 2 hours under a nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure and purified by Prep-HPLC to give the title compound 9.8mg.
1 H NMR(400MHz,DMSO-d 6 )δ8.26(s,1H),7.87(s,1H),7.61(d,J=8.0Hz,1H),7.48(d,J=1.9 Hz,1H),7.43(t,J=7.8Hz,1H),7.06(dd,J=8.0,2.1Hz,1H),3.73(dt,J=7.4,3.6Hz,1H),3.30(s,6H), 2.41(tt,J=8.5,4.7Hz,1H),1.26–1.12(m,2H),1.07(p,J=4.0Hz,2H),1.03–0.94(m,2H),0.94–0.82 (m,2H).
LCMS m/z=419[M+1] +
Example 59 2-cyclopropyl-7- (dimethylamino) -4- [3- (1H-pyrazol-3-yl) phenyl ] - [1,3] thiazolo [4,5-d ] pyrimidin-5-one
Prepared according to the method of example 58 by substituting 1-cyclopropyl-4- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyrazole of step a) into 1-cyclopropyl-3- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrazole.
1 H NMR(400MHz,DMSO-d 6 )δ7.86–7.76(m,2H),7.65(t,J=1.9Hz,1H),7.48(t,J=7.8Hz,1H), 7.20–7.13(m,1H),6.71(d,J=2.4Hz,1H),3.75(tt,J=7.4,3.8Hz,1H),3.30(s,6H),2.42(ddd,J=8.2,6.5, 4.1Hz,1H),1.17(dt,J=8.1,3.5Hz,2H),1.09(dd,J=5.3,2.5Hz,2H),0.97(td,J=7.3,4.8Hz,2H),0.94– 0.80(m,2H).
LCMS m/z=419[M+1] +
Biological Activity test
1. MAT2A enzymology test method
1. Experimental procedure
a) First, 5 XMAT 2AAssay Buffer (250 mM Tris-HCl, pH8.0;250mM KCl;75mM MgCl2;0.025% bsa; 0.05% brij35;1.5mM EDTA), partially diluted to 1X for use;
b) MAT2A enzyme (BPS, 71401) was formulated and added: MAT2A enzyme was formulated with 1 XMAT 2AAssay Buffer to 3.674 ng/. Mu.L (1.67×, final concentration 2.20 ng/. Mu.L), and 15. Mu.L of 1.67 XMAT 2A enzyme solution was added to each of the compound test well and the negative control well, respectively, using a BioTek (MultiFlo FX) automatic liquid separator, while 15. Mu.L of 1 XMAT 2AAssay Buffer was added to the blank control well;
c) Compound preparation and addition: test compounds were diluted from 10mM stock solution to 100. Mu.M using DMSO, and the positive drug AGI-24512 (commercially available) was diluted under the same conditions, and automatically injected into each well using a Tecan compound titrator (D300 e) according to a preset concentration gradient, with a very small injection volume. The concentration gradient was initially 1. Mu.M, diluted 1/2log, and a total of 8 gradients were set. Centrifuging at 2500rpm for 30s, and incubating at 25 ℃ for 30min;
d) Preparing ATP: 10mM TP (Sigma, A7699) was diluted to 700. Mu.M for use using a 1 XMAT 2AAssay Buffer;
e) Preparing and adding a substrate and ATP mixed solution: 5 XMAT 2AAssay Buffer, 3. Mu.L/well; 750 μ M L-metanine (Adamas, 01100469), 2.5 μl/well;700 μMATP,2.5 μL/well; ddH 2 O, 2. Mu.L/well. Preparing the total amount of the required mixed liquid according to the number of detection holes, and adding 10 mu L of the mixed liquid into each hole by using a BioTek (MultiFlo FX) automatic liquid separator; centrifuging at 2500rpm for 30s, and reacting at 25 ℃ for 150min;
f) Biomol Green detection reagent addition: mu.L of Biomol Green (Enzo, BML-AK 111) was added to each well using a BioTek (MultiFlo FX) automatic liquid separator, centrifuged at 2500rpm for 30s, and incubated at 25℃for 20min;
g) After the reaction was completed, OD was read using a Perkin Elmer (Envision 2105) multifunctional plate reader 620 Values.
2. Data analysis
The inhibition rate calculation formula is as follows:
ODsample: OD620 value of sample well;
ODmin: OD620 mean of blank wells representing no enzyme and no test compound;
ODmax: represents the average OD620 of the negative control wells with enzyme and without compound.
The IC50 values for MAT2A enzyme inhibition of the compounds were obtained using GraphPad Prism 5 software log (inhibitor) vs. response-Variable slope fit.
3. Experimental results:
the experimental results of the compounds of the present invention are shown below:
/>
Claims (10)
1. a compound of the general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
wherein:
R 1 or R is 2 Each independently selected from hydrogen, halogen, C1-C6 alkyl or C2-C6 alkynyl;
X 1 selected from N or CR a ;
X 2 Selected from N or CH;
R a selected from hydrogen, halogen, C1-C6 alkyl, amino, hydroxy, amido, 3-6 membered cycloalkyl, 5-7 membered heterocyclyl, benzo five membered heterocyclyl, 5-7 membered heteroaryl orWherein the C1-C6 alkyl is optionally substituted with hydroxy, 5-10 membered aryl, 5-10 membered aryloxy, halogen substituted 5-10 membered aryloxy, or 3-6 membered cycloalkyl, the amido is optionally substituted with C1-C6 alkyl, C1-C6 haloalkyl, 3-6 cycloalkyl, 5-10 membered aryl, halogen substituted 5-10 membered aryl, or halogen substituted 5-10 membered aralkyl, the amino is optionally substituted with 9-12 membered fused ring heteroaryl, 5-10 membered heteroaryl, C1-C3 alkyl substituted 5-10 membered heteroaryl, or pyridinyl substituted 5-10 membered heteroaryl, the hydroxy is optionally substituted with 5-10 membered aralkyl, 5-10 membered heteroaralkyl, halogen substituted 5-10 membered aralkyl, or a benzo five membered heterocyclyl, the 5-7 membered heterocyclyl is optionally substituted with 5-10 membered aryl, the 5-7 membered heteroaryl is optionally substituted with 3-6 membered cycloalkyl;
Alternatively, R a And R is R 1 And form a 3-6 membered heterocyclic ketone group with the carbon atom to which they are attached, said 3-6 membered heterocyclic ketone group being optionally substituted with a 5-7 membered aryl group or a 5-7 membered aralkyl group;
R 3 selected from hydrogen, C1-C6 alkyl, 5-10 membered aryl, C2-C6 alkenyl, 3-6 membered cycloalkyl, C1-C6 alkylthio or C1-C6 sulfonyl, said C1-C6 alkyl being optionally substituted by 3-6 membered cycloalkyl;
R 4 and R is 5 Each independently selected from hydrogen or C1-C6 alkyl.
2. The compound, stereoisomer or pharmaceutically acceptable salt thereof according to claim 1,
R 1 selected from hydrogen, halogen or C2-C3 alkynyl; preferably hydrogen, chlorine or acetylene; more preferably hydrogen or chlorine; most preferably hydrogen;
X 1 is CR (CR) a ;
X 2 Is N;
R a selected from hydrogen, halogen, C1-C3 alkyl, amino, hydroxy, amido, 3-4 membered cycloalkyl, 5 membered heterocyclyl, benzo five membered heterocyclyl containing 1-3 heteroatoms selected from N or O, 5 membered heteroaryl orThe C1-C3 alkyl group is optionally substituted with a hydroxy, 5-7 membered aryl, 5-7 membered aryloxy, halogen substituted 5-7 membered aryloxy, or 3-4 membered cycloalkyl, the amido group is optionally substituted with a C1-C3 alkyl, C1-C3 haloalkyl, 3-4 membered cycloalkyl, 5-7 membered aryl, halogen substituted 5-7 membered aryl, or halogen substituted 5-7 membered aralkyl, the amino group is optionally substituted with a 9 membered fused ring heteroaryl containing 1-3 heteroatoms selected from N or O, a 5-7 membered heteroaryl, a C1-C3 alkyl substituted 5-7 membered heteroaryl, or a pyridinyl substituted 5-7 membered heteroaryl, the hydroxy group is optionally substituted with a 5-7 membered aralkyl, a 5-7 membered heteroaralkyl, a halogen substituted 5-7 membered aralkyl, or a benzo five membered heterocyclyl containing 1-3 heteroatoms selected from N or O, the 5 membered heterocyclyl group is optionally substituted with a 5-7 membered aryl, the 5-membered heteroaryl is optionally substituted with a 3 membered cycloalkyl;
Preferably, R a Selected from the group consisting of hydrogen, bromine, C1-C3 alkyl, amino, hydroxyl, amido, cyclopropyl, The C1-C3 alkyl is optionally substituted with hydroxy, cyclopropyl, phenyl, Substituted, said amide optionally being methyl, trifluoroethyl, cyclopropyl, phenyl,/-> Substituted, said amino group is optionally +.> Substituted, the hydroxy group optionally being Substitution, said->Optionally substituted by phenyl, said ++> Optionally substituted with cyclopropyl;
more preferably, R a Selected from hydrogen, bromine,
Further preferably, R a Selected from hydrogen, bromine,
Still more preferably, R a Selected from bromine,
R a And R is R 1 And form a 5 membered heterocyclic ketone group with the carbon atom to which they are attached, optionally substituted with a 5-7 membered aryl or 5-7 membered aralkyl group;
preferably, R a And R is R 1 Form with the carbon atom to which they are attachedOptionally substituted with phenyl or benzyl;
more preferably, R a And R is R 1 Formation of carbon atoms to which they are attached
R 3 Selected from hydrogen, C1-C3 alkyl, phenyl, C2-C4 alkenyl, 3-4 membered cycloalkyl, C1-C3 alkylthio or C1-C3 sulfonyl, said C1-C3 alkyl being optionally substituted by cyclopropyl;
preferably, R 3 Selected from hydrogen, methyl, ethyl, cyclopropyl, phenyl,
More preferably, R 3 Is cyclopropyl;
R 4 And R is 5 Each independently selected from hydrogen or C1-C3 alkyl; preferably hydrogen or methyl; more preferably, R 4 And R is 5 And is methyl.
3. The compound according to claim 1 or 2, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, further represented by the general formula (II-1):
wherein,
R 1 、R 3 、R 4 and R is 5 The method of claim 1.
4. The compound according to claim 1 or 2, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, further represented by the general formula (II-2):
wherein,
R 3 、R 4 、R 5 and R is a The method of claim 1.
5. The compound according to claim 1 or 2, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, further represented by the general formula (II-3):
wherein R is 3 、R 4 And R is 5 As set forth in the claim 1, the method can be used for the treatment of a cancer,
R 6 selected from hydrogen, phenyl or benzyl.
6. The compound of claim 4, a stereoisomer or pharmaceutically acceptable salt thereof, further represented by the general formula (III):
wherein:
l is selected from the group consisting of bond, -O-, -NH-, - (CH) 2 ) m -、
R C And R is D Each independently selected from hydrogen or C1-C3 alkyl;
ring C is selected from 3-6 membered cycloalkyl, 3-6 membered heterocyclyl, 5-7 membered aryl, 5-7 membered heteroaryl, 5-7 membered heterocyclyl, 9-12 membered fused ring heteroaryl, or benzo five membered heterocyclyl, said 3-6 membered cycloalkyl, 3-6 membered heterocyclyl, 5-7 membered aryl, 5-7 membered heteroaryl, or benzo five membered heterocyclyl optionally being further substituted with halogen, C1-C3 alkyl, 3-6 membered cycloalkyl, 5-7 membered aryl, or 5-7 membered heteroaryl;
R 3 、R 4 、R 5 The method of claim 1;
m is 1 or 2;
z is 0, 1 or 2.
7. The compound, stereoisomer or pharmaceutically acceptable salt thereof according to claim 6,
l is selected from the group consisting of bond, -O-, -NH-, - (CH) 2 ) m -、 Wherein R is C And R is D Each independently selected from hydrogen or methyl, m is 1, z is 0 or 1;
preferably, L is selected from the group consisting of bond, -O-, -NH-, -CH 2 -、
More preferably, L is selected from the group consisting of a bond, -NH-
Ring C is selected from 3-6 membered cycloalkyl, 5-7 membered aryl, 5-7 membered heterocyclyl, 9 membered fused ring heteroaryl, 5-7 membered heteroaryl, optionally substituted with C1-C3 alkyl, 3-6 membered cycloalkyl or 5-7 membered heteroaryl, optionally substituted with halogen, or benzo five membered heterocyclyl containing 1-3 heteroatoms selected from N or O, said 5-7 membered heterocyclyl optionally substituted with 5-7 membered aryl;
preferably, ring C is selected from cyclopropyl, Wherein said->Optionally substituted by methyl or pyridyl, said +.>Optionally substituted with benzene, said ++>Optionally substituted by cyclopropyl, said +.>Optionally substituted with fluorine;
more preferably, ring C is selected from cyclopropyl,
Further preferably, ring C is selected from cyclopropyl,
8. A compound according to any one of claims 1 to 7, a stereoisomer or a pharmaceutically acceptable salt thereof, having the structure:
9. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1-8, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
10. Use of a compound according to claims 1-8, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention and/or treatment of a methionine adenosyltransferase mediated disease or condition according to claim 9.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210741333.4A CN117343081A (en) | 2022-06-28 | 2022-06-28 | MAT2A inhibitor, pharmaceutical composition and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210741333.4A CN117343081A (en) | 2022-06-28 | 2022-06-28 | MAT2A inhibitor, pharmaceutical composition and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117343081A true CN117343081A (en) | 2024-01-05 |
Family
ID=89369717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210741333.4A Pending CN117343081A (en) | 2022-06-28 | 2022-06-28 | MAT2A inhibitor, pharmaceutical composition and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117343081A (en) |
-
2022
- 2022-06-28 CN CN202210741333.4A patent/CN117343081A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102402179B1 (en) | Diaryl macrocycles as modulators of protein kinases | |
JP5808408B2 (en) | Phthalazinone ketone derivative, its production method and pharmaceutical use | |
ES2620316T3 (en) | Cycloalkenopyrazoles substituted as BUB1 inhibitors for cancer treatment | |
EA018808B1 (en) | Protein kinase inhibitors, pharmaceutical composition based thereon and therapeutical use | |
KR102373577B1 (en) | Multikinase inhibitor compounds, crystalline forms and uses thereof | |
JP2016522232A (en) | Heteroaryl-substituted pyrazoles | |
CA3124678A1 (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
JP2016525076A (en) | Substituted benzylpyrazoles | |
EP2590982A1 (en) | Protein kinase inhibitors and methods of treatment | |
CN112608318A (en) | Compound serving as protein kinase inhibitor and application thereof | |
WO2021139775A1 (en) | Pyridone compound and application | |
KR20090015978A (en) | Inhibitors of akt (protein kinase b) | |
KR20240021188A (en) | Checkpoint Kinase 1 (CHK1) Inhibitors and Uses Thereof | |
JP2019522055A (en) | Heterocyclic compounds used as FGFR inhibitors | |
US11142533B2 (en) | Macrocycles for use in treating disease | |
KR20220085735A (en) | Isoxazolidine derivative compounds, and uses thereof | |
TW202204351A (en) | Compounds having a macrocyclic structure and uses thereof | |
ES2927529T3 (en) | condensed heterocyclic compound | |
CA3093323C (en) | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | |
KR100298523B1 (en) | Amide derivatives | |
CA2983040C (en) | Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof | |
CN114437116A (en) | Heterocyclic compound and preparation method, pharmaceutical composition and application thereof | |
CN109988151B (en) | Acetylene compound, preparation method and application thereof | |
AU2014284013B2 (en) | Five-membered heterocyclic pyridine compounds and preparation method and use thereof | |
WO2023230477A1 (en) | Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |